{"content":"<li class=\"n-box-item date-title\" data-end=\"1540267199\" data-start=\"1540180800\" data-txt=\"Monday, December 23, 2019\">Monday, October 22, 2018</li><li class=\"n-box-item sa-box-item\" data-id=\"3399511\" data-ts=\"1540257757\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARNC\" target=\"_blank\">ARNC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399511-reuters-arconic-weighs-11b-offer-from-apollo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Reuters: Arconic weighs $11B offer from Apollo</a></h4><ul>     <li>Arconic (NYSE:<a href='https://seekingalpha.com/symbol/ARNC' title='Arconic Inc'>ARNC</a>)&nbsp;<font color='green'>+4.9%</font> after-hours following a Reuters report that its board is <a href=\"https://www.reuters.com/article/us-arconic-m-a-apollo-glo-mgmt/arconic-weighs-11-billion-offer-from-apollo-sources-idUSKCN1MW2YU?il=0\" target=\"_blank\">considering an $11B takeover offer</a> received last Friday from Apollo Global Management (NYSE:<a href='https://seekingalpha.com/symbol/APO' title='Apollo Global Management, LLC'>APO</a>), valuing ARNC at $23-$24/share.</li>     <li>Another bidding group comprising buyout firms Blackstone (NYSE:<a href='https://seekingalpha.com/symbol/BX' title='The Blackstone Group L.P.'>BX</a>), Carlyle (NASDAQ:<a href='https://seekingalpha.com/symbol/CG' title='The Carlyle Group'>CG</a>), Onex (<a href='https://seekingalpha.com/symbol/ONEXF' title='Onex Corporation'>OTCPK:ONEXF</a>) and Canada Pension Plan Investment Board reportedly has not yet submitted an offer for ARNC, and it is not clear whether it will submit a bid to rival APO in the coming days.</li>     <li>ARNC has not set a firm bid deadline and no deal is imminent, although it hopes to reach a decision on whether it will sell itself by its investor day next month, according to the report.</li></ul><div class=\"tiny-share-widget\" data-id=\"3399511\" data-linked=\"Reuters: Arconic weighs $11B offer from Apollo\" data-tweet=\"$ARNC $ARNC $APO - Reuters: Arconic weighs $11B offer from Apollo https://seekingalpha.com/news/3399511-reuters-arconic-weighs-11b-offer-from-apollo?source=tweet\" data-url=\"https://seekingalpha.com/news/3399511-reuters-arconic-weighs-11b-offer-from-apollo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>41&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399507\" data-ts=\"1540246343\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CR\" target=\"_blank\">CR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399507-craneplus-3-after-q3-earnings-beat-raises-full-year-earnings-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Crane +3% after Q3 earnings beat; raises full-year earnings guidance</a></h4><ul>     <li>Crane (NYSE:<a href='https://seekingalpha.com/symbol/CR' title='Crane Co.'>CR</a>)&nbsp;<font color='green'>+3%</font> after-hours as the industrial firm easily beats <a href=\"https://seekingalpha.com/news/3399474-crane-beats-0_16-revenue-line\" target=\"_blank\">Q3 earnings</a> estimates and raises full-year earnings guidance above consensus.</li>     <li>Q3 sales totaled a record $856M, up 23% Y/Y, comprised of a $132M benefit from acquisitions and $40M in core sales growth, partially offset by $12M of unfavorable foreign exchange.</li>     <li>CR says it is tracking ahead of the midpoint of previously issued guidance, driven by further strengthening in its Aerospace &amp; Electronics and Crane  Currency markets, prompting it to raise FY 2018 adjusted EPS guidance to $5.80-$5.90 from its prior outlook of $5.60-$5.80 and above the $5.75 analyst consensus estimate.</li>     <li>CR also bumps its free cash flow forecast to $260M-$290M from previous guidance of $250M-$280M.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3399507\" data-linked=\"Crane +3% after Q3 earnings beat; raises full-year earnings guidance\" data-tweet=\"$CR - Crane +3% after Q3 earnings beat; raises full-year earnings guidance https://seekingalpha.com/news/3399507-craneplus-3-after-q3-earnings-beat-raises-full-year-earnings-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3399507-craneplus-3-after-q3-earnings-beat-raises-full-year-earnings-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:12 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399492\" data-ts=\"1540244134\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RGLS\" target=\"_blank\">RGLS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399492-after-hours-rgls-cdns-gain-gecc-mack-lose\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After hours: RGLS, CDNS gain; GECC, MACK lose</a></h4><ul><li><b>Top Gainers:</b>&nbsp;<a href='https://seekingalpha.com/symbol/RGLS' title='Regulus Therapeutics'>RGLS</a>&nbsp;<font color='green'>+42.1%</font>. <a href='https://seekingalpha.com/symbol/CDNS' title='Cadence Design Systems, Inc.'>CDNS</a>&nbsp;<font color='green'>+9.0%</font>. <a href='https://seekingalpha.com/symbol/SENS' title='Senseonics Holdings'>SENS</a>&nbsp;<font color='green'>+7.5%</font>. <a href='https://seekingalpha.com/symbol/SSNC' title='SS&C Technologies Holdings, Inc.'>SSNC</a>&nbsp;<font color='green'>+6.3%</font>. <a href='https://seekingalpha.com/symbol/I' title='Intelsat SA'>I</a>&nbsp;<font color='green'>+3.4%</font>.</li><li><b>Top Losers:</b> <a href='https://seekingalpha.com/symbol/GECC' title='Great Elm Capital Corp'>GECC</a> <font color='red'>-19.0%</font>. <a href='https://seekingalpha.com/symbol/MC' title='Moelis & Company'>MC</a>&nbsp;<font color='red'>-9.1%</font>.&nbsp;<a href='https://seekingalpha.com/symbol/FLEX' title='Flex Ltd..'>FLEX</a> <font color='red'>-4.3%</font>. <a href='https://seekingalpha.com/symbol/BZUN' title='Baozun'>BZUN</a>&nbsp;<font color='red'>-3.6%.</font>&nbsp;<a href='https://seekingalpha.com/symbol/MACK' title='Merrimack Pharmaceuticals'>MACK</a> <font color='red'>-3.4%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3399492\" data-linked=\"After hours: RGLS, CDNS gain; GECC, MACK lose\" data-tweet=\"$RGLS $RGLS $CDNS - After hours: RGLS, CDNS gain; GECC, MACK lose https://seekingalpha.com/news/3399492-after-hours-rgls-cdns-gain-gecc-mack-lose?source=tweet\" data-url=\"https://seekingalpha.com/news/3399492-after-hours-rgls-cdns-gain-gecc-mack-lose\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399474\" data-ts=\"1540242642\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CR\" target=\"_blank\">CR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399474-crane-beats-0_16-revenue-in-line\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Crane beats by $0.16,  revenue in-line</a></h4><ul><li>Crane (NYSE:<a href='https://seekingalpha.com/symbol/CR' title='Crane Co.'>CR</a>): Q3 Non-GAAP EPS of $1.62 beats by $0.16.</li><li>Revenue of $855.8M (+23.0% Y/Y) in-line.</li><li>Shares <font color='green'>+3.06%</font> AH.</li><li><a href=\"https://seekingalpha.com/pr/17308062-crane-co-reports-2018-third-quarter-results-raises-full-year-eps-guidance\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3399474\" data-linked=\"Crane beats by $0.16,  revenue in-line\" data-tweet=\"$CR - Crane beats by $0.16, revenue in-line https://seekingalpha.com/news/3399474-crane-beats-0_16-revenue-in-line?source=tweet\" data-url=\"https://seekingalpha.com/news/3399474-crane-beats-0_16-revenue-in-line\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:10 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399457\" data-ts=\"1540241594\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SENS\" target=\"_blank\">SENS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399457-senseonics-up-8-after-hours-on-aetna-coverage-for-eversense\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Senseonics up 8% after hours on Aetna coverage for Eversense</a></h4><ul><li>Senseonics (NYSEMKT:<a href='https://seekingalpha.com/symbol/SENS' title='Senseonics Holdings'>SENS</a>) is up&nbsp;<font color='green'>8%</font>&nbsp;after hours on the <a href=\"https://seekingalpha.com/pr/17308017-senseonics-announces-aetna-s-positive-coverage-decision-eversense\" target=\"_blank\">news </a>that Aetna will cover its Eversense continuous glucose monitor effective immediately.</li><li>Competitor DexCom (NASDAQ:<a href='https://seekingalpha.com/symbol/DXCM' title='DexCom, Inc.'>DXCM</a>) is down&nbsp;<font color='red'>1%</font>&nbsp;after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3399457\" data-linked=\"Senseonics up 8% after hours on Aetna coverage for Eversense\" data-tweet=\"$SENS $SENS $DXCM - Senseonics up 8% after hours on Aetna coverage for Eversense https://seekingalpha.com/news/3399457-senseonics-up-8-after-hours-on-aetna-coverage-for-eversense?source=tweet\" data-url=\"https://seekingalpha.com/news/3399457-senseonics-up-8-after-hours-on-aetna-coverage-for-eversense\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:53 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399448\" data-ts=\"1540240995\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AFMD\" target=\"_blank\">AFMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399448-affimed-files-for-150m-mixed-shelf-offering-shares-down-2-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Affimed files for $150M mixed shelf offering; shares down 2% after hours</a></h4><ul><li>Affimed N.V. (NASDAQ:<a href='https://seekingalpha.com/symbol/AFMD' title='Affimed Therapeutics'>AFMD</a>) has filed a <a href=\"https://www.sec.gov/Archives/edgar/data/1608390/000095010318012289/dp97189_f3.htm\" target=\"_blank\">prospectus </a>for a $150M mixed shelf offering. Shares are off&nbsp;<font color='red'>2%</font>&nbsp;after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3399448\" data-linked=\"Affimed files for $150M mixed shelf offering; shares down 2% after hours\" data-tweet=\"$AFMD - Affimed files for $150M mixed shelf offering; shares down 2% after hours https://seekingalpha.com/news/3399448-affimed-files-for-150m-mixed-shelf-offering-shares-down-2-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3399448-affimed-files-for-150m-mixed-shelf-offering-shares-down-2-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399432\" data-ts=\"1540240018\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SSNC\" target=\"_blank\">SSNC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399432-ss-and-cplus-6-on-upside-preliminary-q3-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SS&amp;C +6% on upside preliminary Q3 results</a></h4><ul><li>        SS&amp;C Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/SSNC' title='SS&C Technologies Holdings, Inc.'>SSNC</a>) <a href=\"https://seekingalpha.com/pr/17307923-ss-and-c-technologies-reports-selected-preliminary-third-quarter-2018-results\" target=\"_blank\">provides</a> preliminary Q3 results with adjusted net income of $196.9M to $199.8M (was: $162M to $168M; consensus: $166.4M) and adjusted EPS of $0.78 to $0.79 (consensus: $0.66).</li><li>                  Management cites the lower cost structure and particular strength in DST and expects to &ldquo;significantly outperform our $175M, three-year synergy target.&rdquo;    </li><li>               SS&amp;C shares are&nbsp;<font color='green'>up 6.1%</font>&nbsp;aftermarket to $52.95.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3399432\" data-linked=\"SS&amp;C +6% on upside preliminary Q3 results\" data-tweet=\"$SSNC - SS&amp;C +6% on upside preliminary Q3 results https://seekingalpha.com/news/3399432-ss-and-cplus-6-on-upside-preliminary-q3-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3399432-ss-and-cplus-6-on-upside-preliminary-q3-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:26 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399417\" data-ts=\"1540239580\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CDNS\" target=\"_blank\">CDNS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399417-cadence-designplus-8_3-on-q3-beats-upside-guide\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cadence Design +8.3% on Q3 beats, upside guide</a></h4><ul><li>        Cadence Design Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/CDNS' title='Cadence Design Systems, Inc.'>CDNS</a>) shares are&nbsp;<font color='green'>up 8.3%&nbsp;</font>aftermarket on Q3 beats with a 10% Y/Y revenue growth. Upside Q4 guidance has revenue of $545M to $555M (consensus: $529.57M) and EPS of $0.46 to $0.48 (consensus: $0.42).</li><li>The earnings webcast is scheduled for 5 PM and will be available<a href=\"https://www.cadence.com/content/cadence-www/global/en_US/home/company/investors.html\" target=\"_blank\"> here</a>. &nbsp;</li><li>        <a href=\"https://seekingalpha.com/pr/17307910-cadence-reports-third-quarter-2018-financial-results\" target=\"_blank\">Press release</a>.&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3399404-cadence-design-systems-beats-0_08-beats-revenue\" target=\"_blank\">Cadence Design Systems beats by $0.08, beats on revenue</a> (Oct. 22)</li></ul><div class=\"tiny-share-widget\" data-id=\"3399417\" data-linked=\"Cadence Design +8.3% on Q3 beats, upside guide\" data-tweet=\"$CDNS - Cadence Design +8.3% on Q3 beats, upside guide https://seekingalpha.com/news/3399417-cadence-designplus-8_3-on-q3-beats-upside-guide?source=tweet\" data-url=\"https://seekingalpha.com/news/3399417-cadence-designplus-8_3-on-q3-beats-upside-guide\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:19 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399409\" data-ts=\"1540239013\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EIGR\" target=\"_blank\">EIGR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399409-eiger-bio-readies-stock-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eiger Bio readies stock offering</a></h4><ul><li>Eiger BioPharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/EIGR' title='Eiger BioPharmaceuticals, Inc.'>EIGR</a>) <a href=\"https://seekingalpha.com/pr/17307885-eiger-biopharmaceuticals-announces-proposed-public-offering-common-stock\" target=\"_blank\">initiates </a>a public stock offering. Price, volume and terms have yet to announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3399409\" data-linked=\"Eiger Bio readies stock offering\" data-tweet=\"$EIGR - Eiger Bio readies stock offering https://seekingalpha.com/news/3399409-eiger-bio-readies-stock-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3399409-eiger-bio-readies-stock-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:10 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399406\" data-ts=\"1540238899\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTI\" target=\"_blank\">PTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399406-proteostasis-launches-9m-share-stock-offering-shares-down-1-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Proteostasis launches 9M-share stock offering; shares down 1% after hours</a></h4><ul><li>Proteostasis Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics'>PTI</a>) slips&nbsp;<font color='red'>1%</font>&nbsp;after hours in reaction to its planned <a href=\"https://seekingalpha.com/pr/17307887-proteostasis-therapeutics-announces-proposed-public-offering-common-stock\" target=\"_blank\">public offering</a> of 9M shares of common stock. Underwriters over-allotment will be an additional 1.35M shares. Price and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3399406\" data-linked=\"Proteostasis launches 9M-share stock offering; shares down 1% after hours\" data-tweet=\"$PTI - Proteostasis launches 9M-share stock offering; shares down 1% after hours https://seekingalpha.com/news/3399406-proteostasis-launches-9m-share-stock-offering-shares-down-1-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3399406-proteostasis-launches-9m-share-stock-offering-shares-down-1-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:08 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399402\" data-ts=\"1540238610\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMTD\" target=\"_blank\">AMTD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399402-td-ameritrade-beats-0_04-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TD Ameritrade beats by $0.04, beats on revenue</a></h4><ul><li>TD Ameritrade (NASDAQ:<a href='https://seekingalpha.com/symbol/AMTD' title='TD Ameritrade Holding Corporation'>AMTD</a>): Q4 Non-GAAP EPS of $0.92 beats by $0.04; GAAP EPS of $0.80 beats by $0.02.</li><li>Revenue of $1.4B (+42.4% Y/Y) <font color='green'>beats by $10M</font>.</li><li>Shares <font color='green'>+1.1%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17307883-td-ameritrade-reports-record-fiscal-2018-earnings\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3399402\" data-linked=\"TD Ameritrade beats by $0.04, beats on revenue\" data-tweet=\"$AMTD - TD Ameritrade beats by $0.04, beats on revenue https://seekingalpha.com/news/3399402-td-ameritrade-beats-0_04-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3399402-td-ameritrade-beats-0_04-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399397\" data-ts=\"1540238238\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMSSY\" target=\"_blank\">AMSSY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399397-ams-ag-adr-reports-q3-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AMS AG ADR reports Q3 results</a></h4><ul><li>AMS AG ADR (<a href='https://seekingalpha.com/symbol/AMSSY' title='AMS AG ADR'>OTCPK:AMSSY</a>): Q3 Non-GAAP EPS of $0.22.</li><li>Revenue of $479.6M (+57.0% Y/Y)</li><li>Shares <font color='green'>+7%</font>.</li><li><a href=\"https://ams.com/-/10-22-2018-ams-financial-results-q3-2018\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3399397\" data-linked=\"AMS AG ADR reports Q3 results\" data-tweet=\"$AMSSY $AUKUF - AMS AG ADR reports Q3 results https://seekingalpha.com/news/3399397-ams-ag-adr-reports-q3-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3399397-ams-ag-adr-reports-q3-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399396\" data-ts=\"1540238133\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EBAY\" target=\"_blank\">EBAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399396-52-week-low-for-ebay-week-ahead-of-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">52-week low for eBay a week ahead of earnings</a></h4><ul> <li>Shares of eBay (<a href='https://seekingalpha.com/symbol/EBAY' title='eBay Inc.'>EBAY</a> <font color='red'>-0.7%</font>) drifted down to a 52-week low of $28.09 earlier in the session after a pair of Wall Street <a href=\"https://seekingalpha.com/news/3399171-ebay-watch-pair-downgrades\" target=\"_blank\">downgrades</a> arrived on market share concerns.</li> <li>\"In addition to Amazon.com's continued share gains, eBay is increasingly under pressure from traditional brick-and-mortar retailers who have been investing heavily in technology, logistics and brands,\" observes analyst Jim Chartier.</li> <li>\"Walmart and Target are growing their U.S. e-commerce businesses 40% and 30%, respectively, which equates to $5 billion-$6 billion of combined sales growth,\" he adds.</li> <li>Monness dropped its Q3 EPS estimate to $0.54 due to the lower sales projection vs. $0.55 consensus.</li> <li>For its part, Bank of America Merrill Lynch expressed a lack of confidence on the company's near-term execution.</li> <li>EBay is due to report earnings next week.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3399396\" data-linked=\"52-week low for eBay a week ahead of earnings\" data-tweet=\"$EBAY - 52-week low for eBay a week ahead of earnings https://seekingalpha.com/news/3399396-52-week-low-for-ebay-week-ahead-of-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3399396-52-week-low-for-ebay-week-ahead-of-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399394\" data-ts=\"1540237785\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SCG\" target=\"_blank\">SCG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399394-scanaminus-11-says-judge-order-finds-states-base-load-review-unconstitutional\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SCANA -11%; says judge order finds state&#39;s base load review unconstitutional</a></h4><ul>     <li>Trading resumes in SCANA (<a href='https://seekingalpha.com/symbol/SCG' title='SCANA Corporation'>SCG</a> <font color='red'>-11%</font>) after a halt, as the company issues a statement confirming that the circuit court judge in the customer class action in South Carolina has said the Base Load Review Act <a href=\"https://seekingalpha.com/pr/17307855-scana-corporation-issues-statement\" target=\"_blank\">violates the state's constitution</a>.</li>     <li>The company says the judge last week \"provided instructions to counsel for the plaintiffs and the state that... directed the attorneys to include language in the proposed orders stating, among other things, that the Base Load Review Act violates the procedural due process provisions of the South Carolina Constitution.\"</li>     <li>SCG says it will provide the judge with comments to the  proposed orders by Oct. 29, and the judge has \"indicated to the attorneys for the parties that no final decision has been reached at this time, and the aforementioned issues will remain unresolved until he signs an order in the matter.\"</li>     <li><a href=\"https://seekingalpha.com/news/3399361-scana-minus-8-percent-report-judge-likely-overturn-base-load-review\" target=\"_blank\">Earlier</a>:&nbsp;SCANA -8% on report judge likely to overturn base load review (Oct. 22)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3399394\" data-linked=\"SCANA -11%; says judge order finds state&#39;s base load review unconstitutional\" data-tweet=\"$SCG - SCANA -11%; says judge order finds state&#39;s base load review unconstitutional https://seekingalpha.com/news/3399394-scanaminus-11-says-judge-order-finds-states-base-load-review-unconstitutional?source=tweet\" data-url=\"https://seekingalpha.com/news/3399394-scanaminus-11-says-judge-order-finds-states-base-load-review-unconstitutional\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399390\" data-ts=\"1540237579\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PETX\" target=\"_blank\">PETX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399390-aratana-up-12-on-potential-sale\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aratana up 12% on potential sale</a></h4><ul><li>Takeover rumor du jour is Aratana Therapeutics (<a href='https://seekingalpha.com/symbol/PETX' title='Aratana Therapeutics'>PETX</a> <font color='green'>+11.9%</font>), up on more than triple normal on rumors that it is considering a sale.</li></ul><div class=\"tiny-share-widget\" data-id=\"3399390\" data-linked=\"Aratana up 12% on potential sale\" data-tweet=\"$PETX - Aratana up 12% on potential sale https://seekingalpha.com/news/3399390-aratana-up-12-on-potential-sale?source=tweet\" data-url=\"https://seekingalpha.com/news/3399390-aratana-up-12-on-potential-sale\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399387\" data-ts=\"1540237287\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AZN\" target=\"_blank\">AZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399387-astrazenecas-lynparza-shows-positive-effect-in-late-stage-ovarian-cancer-study-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AstraZeneca&#39;s Lynparza shows positive effect in late-stage ovarian cancer study; shares up 1%</a></h4><ul><li>AstraZeneca (<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca Group plc'>AZN</a> <font color='green'>+0.8%</font>) is up on average volume following its <a href=\"https://www.astrazeneca.com/media-centre/press-releases/2018/solo-1-phase-III-trial-demonstrates-lynparza-maintenance-therapy-cut-risk-of-disease-progression-or-death-by-70-percent-in-patients-with-newly-diagnosed-advanced-brca-mutated-ovarian-cancer.html\" target=\"_blank\">announcement </a>of results from a Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT01844986?titles=solo-1&amp;lead=astrazeneca&amp;phase=2&amp;rank=1\" target=\"_blank\">SOLO-1</a>, evaluating PARP inhibitor Lynparza (olaparib) in newly diagnosed patients with BRCA mutation-positive ovarian cancer who are in complete or partial response after first-line platinum-based chemo.</li><li>Treated patients experienced 70% less risk of disease progression of death compared to placebo. 60% remained progression-free at month 36 versus 27% for control.</li><li>Related tickers: (<a href='https://seekingalpha.com/symbol/TSRO' title='Tesaro'>TSRO</a> <font color='red'>-11.3%</font>)(<a href='https://seekingalpha.com/symbol/CLVS' title='Clovis Oncology'>CLVS</a> <font color='red'>-18.8%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3399387\" data-linked=\"AstraZeneca&#39;s Lynparza shows positive effect in late-stage ovarian cancer study; shares up 1%\" data-tweet=\"$AZN $AZN $TSRO - AstraZeneca&#39;s Lynparza shows positive effect in late-stage ovarian cancer study; shares up 1% https://seekingalpha.com/news/3399387-astrazenecas-lynparza-shows-positive-effect-in-late-stage-ovarian-cancer-study-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3399387-astrazenecas-lynparza-shows-positive-effect-in-late-stage-ovarian-cancer-study-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399388\" data-ts=\"1540237284\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FB\" target=\"_blank\">FB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399388-oppenheimer-names-picks-for-facebooks-cybersecurity-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oppenheimer names its picks for Facebook&#39;s cybersecurity buy</a></h4><ul><li>        Oppenheimer names its top picks for Facebook&rsquo;s (<a href='https://seekingalpha.com/symbol/FB' title='Facebook'>FB</a> <font color='green'>+0.9%</font>) potential cybersecurity acquisition: Fortinet (<a href='https://seekingalpha.com/symbol/FTNT' title='Fortinet, Inc.'>FTNT</a> <font color='green'>+2.5%</font>), Palo Alto Networks (<a href='https://seekingalpha.com/symbol/PANW' title='Palo Alto Networks'>PANW</a> <font color='green'>+0.7%</font>), Check Point Software (<a href='https://seekingalpha.com/symbol/CHKP' title='Check Point Software Technologies Ltd.'>CHKP</a> <font color='green'>+2.6%</font>), Splunk (<a href='https://seekingalpha.com/symbol/SPLK' title='Splunk Inc.'>SPLK</a> <font color='green'>+2.1%</font>), and FireEye (<a href='https://seekingalpha.com/symbol/FEYE' title='FireEye, Inc.'>FEYE</a> <font color='green'>+4.2%</font>).</li><li>               Source: Briefing.com.&nbsp;</li><li>               The Information reported that Facebook wants to buy a major cybersecurity player potentially before the end of the year. Sources say Facebook has already held talks with several companies. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3399235-report-facebook-wants-buy-major-cybersecurity-company\" target=\"_blank\">Report: Facebook wants to buy major cybersecurity company</a> (Oct. 22)</li></ul><div class=\"tiny-share-widget\" data-id=\"3399388\" data-linked=\"Oppenheimer names its picks for Facebook&#39;s cybersecurity buy\" data-tweet=\"$FB $FB $FTNT - Oppenheimer names its picks for Facebook&#39;s cybersecurity buy https://seekingalpha.com/news/3399388-oppenheimer-names-picks-for-facebooks-cybersecurity-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3399388-oppenheimer-names-picks-for-facebooks-cybersecurity-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>42&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399380\" data-ts=\"1540236785\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSRO\" target=\"_blank\">TSRO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399380-tesaros-zejula-shows-30-response-rate-in-late-line-ovarian-cancer-shares-under-pressure-on\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tesaro&#39;s Zejula shows 30% response rate in late-line ovarian cancer; shares under pressure on Lynparza data, down 11%</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/17306662-tesaro-announces-data-presentations-esmo-2018-congress\" target=\"_blank\">Updated data</a> from a Phase 1 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02715284?intr=TSR-042&amp;lead=tesaro&amp;rank=1\" target=\"_blank\">GARNET</a>, evaluating TESARO's (<a href='https://seekingalpha.com/symbol/TSRO' title='Tesaro'>TSRO</a> <font color='red'>-10.7%</font>) PD-1 inhibitor TSR-042 in patients with recurrent/advanced microsatellite instability high (MSI-H) (tumors are mutating at a high rate) endometrial cancer showed a treatment effect. The results were presented at ESMO in Munich.</li><li>35 patients were treated. In 25 evaluable patients, the response rate was 52% (n=13/25), including one complete responder. The disease control rate &#40;DCR&#41; (responders + stable cancer) was 64% (n=16/25).</li><li>The results will support a U.S. marketing application to be filed in 2019.</li><li>Separately, additional data from the Phase 2 <a href=\"https://clinicaltrials.gov/ct2/show/NCT02354586?titles=quadra&amp;lead=tesaro&amp;rank=1\" target=\"_blank\">QUADRA </a>study evaluating Zejula (niraparib) in late-line ovarian cancer patients regardless of biomarker status showed a response rate of 30% and a DCR of 56% at week 16 and 38% at week 24.</li><li>TESARO and Clovis Oncology (<a href='https://seekingalpha.com/symbol/CLVS' title='Clovis Oncology'>CLVS</a> <font color='red'>-18.2%</font>) are apparently being pressured late-stage by data on AstraZeneca's (<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca Group plc'>AZN</a> <font color='green'>+0.9%</font>) PARP inhibitor Lynparza (olaparib) in ovarian cancer.</li><li>#ESMO</li></ul><div class=\"tiny-share-widget\" data-id=\"3399380\" data-linked=\"Tesaro&#39;s Zejula shows 30% response rate in late-line ovarian cancer; shares under pressure on Lynparza data, down 11%\" data-tweet=\"$TSRO $TSRO $CLVS - Tesaro&#39;s Zejula shows 30% response rate in late-line ovarian cancer; shares under pressure on Lynparza data, down 11% https://seekingalpha.com/news/3399380-tesaros-zejula-shows-30-response-rate-in-late-line-ovarian-cancer-shares-under-pressure-on?source=tweet\" data-url=\"https://seekingalpha.com/news/3399380-tesaros-zejula-shows-30-response-rate-in-late-line-ovarian-cancer-shares-under-pressure-on\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:33 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399372\" data-ts=\"1540235318\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LITE\" target=\"_blank\">LITE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399372-lumentum-down-on-competitors-weak-margins\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lumentum down on competitor&#39;s weak margins</a></h4><ul><li>        Rosenblatt analyst Jun Zhang attributes Lumentum&rsquo;s (NASDAQ:<a href='https://seekingalpha.com/symbol/LITE' title='Lumentum Holdings Inc.'>LITE</a>) drop to 3D sensing component competitor AMS reporting disappointing gross margins.</li><li>               AMS said 3D sensing design wins for Xiaomi and another major Android OEM have moved to production and noted two design wins in Android time-of-flight 3D systems for two Asian smartphone manufacturers.&nbsp;</li><li>               Source: Bloomberg First Word.&nbsp;</li><li>               Lumentum shares are&nbsp;<font color='red'>down 5%</font>&nbsp;to $58.99.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3399372\" data-linked=\"Lumentum down on competitor&#39;s weak margins\" data-tweet=\"$LITE - Lumentum down on competitor&#39;s weak margins https://seekingalpha.com/news/3399372-lumentum-down-on-competitors-weak-margins?source=tweet\" data-url=\"https://seekingalpha.com/news/3399372-lumentum-down-on-competitors-weak-margins\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399367\" data-ts=\"1540234739\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NETE\" target=\"_blank\">NETE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399367-microcaps-top-list-of-technology-movers-10-22-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Microcaps top list of technology movers (10/22/2018)</a></h4><ul>     <li><strong>Gainers:</strong> <a href='https://seekingalpha.com/symbol/NETE' title='Net Element International, Inc.'>NETE</a> <font color='green'>+37%</font>. <a href='https://seekingalpha.com/symbol/GRVY' title='GRAVITY Co., Ltd. - American depositary shares, each representing one'>GRVY</a> <font color='green'>+25%</font>. <a href='https://seekingalpha.com/symbol/CRNT' title='Ceragon Networks Ltd.'>CRNT</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/NH' title='NantHealth'>NH</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/BITA' title='Bitauto Holdings Limited'>BITA</a> <font color='green'>+7%</font>.</li>     <li><strong>Losers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/NCTY' title='The9 Limited'>NCTY</a> <font color='red'>-23%</font>. <a href='https://seekingalpha.com/symbol/ABIL' title='Ability Inc.'>ABIL</a> <font color='red'>-21%</font>. <a href='https://seekingalpha.com/symbol/JMU' title='JMU Limited'>JMU</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/ELTK' title='Eltek Ltd.'>ELTK</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/RENN' title='Renren Inc.'>RENN</a> <font color='red'>-11%</font>.</li>      &nbsp; </ul><div class=\"tiny-share-widget\" data-id=\"3399367\" data-linked=\"Microcaps top list of technology movers (10/22/2018)\" data-tweet=\"$NETE $NETE $GRVY - Microcaps top list of technology movers (10/22/2018) https://seekingalpha.com/news/3399367-microcaps-top-list-of-technology-movers-10-22-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3399367-microcaps-top-list-of-technology-movers-10-22-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399366\" data-ts=\"1540234628\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VALE\" target=\"_blank\">VALE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399366-brazil-pension-fund-previ-says-will-not-sell-vale-shares-year-end\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Brazil pension fund Previ says it will not sell Vale shares before year-end</a></h4><ul>     <li>Vale (<a href='https://seekingalpha.com/symbol/VALE' title='Vale S.A.'>VALE</a> <font color='green'>+3.1%</font>) is higher after top Brazil pension fund Previ, one of the miner&rsquo;s largest shareholders, says it <a href=\"https://www.reuters.com/article/vale-sa-previ-stocks/update-1-brazilian-pension-fund-previ-wont-sell-vale-shares-before-yr-end-ceo-idUSL2N1X20JM\" target=\"_blank\">will not sell</a> part of its stake before the end of the year.</li>     <li>Previ, which manages pensions for employees of Banco do Brasil, prompted speculation when it changed the way it accounts for the stake in its financial statements, marking Vale shares monthly at an average market value of the previous 90 days after previously revising the share price only once a year.</li>     <li>Previ CEO Jose Mauricio Coelho does say the fund intendes to reduce its stake in Vale over the medium term.</li></ul><div class=\"tiny-share-widget\" data-id=\"3399366\" data-linked=\"Brazil pension fund Previ says it will not sell Vale shares before year-end\" data-tweet=\"$VALE - Brazil pension fund Previ says it will not sell Vale shares before year-end https://seekingalpha.com/news/3399366-brazil-pension-fund-previ-says-will-not-sell-vale-shares-year-end?source=tweet\" data-url=\"https://seekingalpha.com/news/3399366-brazil-pension-fund-previ-says-will-not-sell-vale-shares-year-end\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:57 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399364\" data-ts=\"1540234540\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTGX\" target=\"_blank\">PTGX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399364-protagonists-ptgminus-100-shows-clinical-remission-rates-high-15_8-in-uc-study-investors\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Protagonist&#39;s PTG-100 shows clinical remission rates at high as 15.8% in UC study; investors unmoved, shares down 7%</a></h4><ul><li>Thinly traded micro cap Protagonist Therapeutics (<a href='https://seekingalpha.com/symbol/PTGX' title='Protagonist Therapeutics'>PTGX</a> <font color='red'>-6.9%</font>) is down on below-average volume following its <a href=\"https://seekingalpha.com/pr/17307242-protagonist-therapeutics-presents-clinical-data-propel-study-ptgminus-100-ulcerative-colitis\" target=\"_blank\">announcement </a>of results from the Phase 2 <a href=\"https://clinicaltrials.gov/ct2/show/NCT02895100?lead=protagonist&amp;rank=1\" target=\"_blank\">PROPEL </a>study evaluating PTG-100 in patients with moderate-to-severe ulcerative colitis &#40;UC&#41;. The data were presented at UEGW conference in Vienna.</li><li>The clinical remission rates for the 150 mg, 300 mg and 900 mg doses were 9.1%, 9.5% and 15.8%, respectively. On a histology basis, the remission rates were 15.%, 22% and 44%, respectively.</li><li>The company says a human error in initial endoscopy reads by the original vendor that led to an unusually high placebo effect (23.5%) was the cause of the study failure reported in March.</li><li>PTG-100 is an oral alpha4beta7 integrin antagonist. Alpha4beta7 binds to a protein called&nbsp;<a href=\"https://en.wikipedia.org/wiki/Addressin\" target=\"_blank\">MAdCAM-1</a>&nbsp;that resides in the GI vasculature that acts as a homing receptor for white blood cells called lymphocytes. Blocking the receptors lowers the levels of lymphocytes which lessens inflammation.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3341463-protagonist-bails-mid-stage-ptgminus-100-uc\" target=\"_blank\">Protagonist bails on mid-stage of PTG-100 in UC</a> (March 26)</li></ul><div class=\"tiny-share-widget\" data-id=\"3399364\" data-linked=\"Protagonist&#39;s PTG-100 shows clinical remission rates at high as 15.8% in UC study; investors unmoved, shares down 7%\" data-tweet=\"$PTGX - Protagonist&#39;s PTG-100 shows clinical remission rates at high as 15.8% in UC study; investors unmoved, shares down 7% https://seekingalpha.com/news/3399364-protagonists-ptgminus-100-shows-clinical-remission-rates-high-15_8-in-uc-study-investors?source=tweet\" data-url=\"https://seekingalpha.com/news/3399364-protagonists-ptgminus-100-shows-clinical-remission-rates-high-15_8-in-uc-study-investors\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:55 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399365\" data-ts=\"1540234471\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LFGP\" target=\"_blank\">LFGP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399365-ledyard-financial-group-reports-q3-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ledyard Financial Group reports Q3 results</a></h4><ul><li>Ledyard Financial Group (<a href='https://seekingalpha.com/symbol/LFGP' title='Ledyard Financial Group, Inc.'>OTCQB:LFGP</a>): Q3 GAAP EPS of $0.44.</li><li>Revenue of $6.92M (+8.3% Y/Y)</li><li>Shares <font color='green'>+2.1%</font>.</li><li><a href='https://seekingalpha.com/pr/17307826-ledyard-financial-group-reports-record-quarterly-earnings'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3399365\" data-linked=\"Ledyard Financial Group reports Q3 results\" data-tweet=\"$LFGP - Ledyard Financial Group reports Q3 results https://seekingalpha.com/news/3399365-ledyard-financial-group-reports-q3-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3399365-ledyard-financial-group-reports-q3-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:54 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399361\" data-ts=\"1540233328\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SCG\" target=\"_blank\">SCG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399361-scanaminus-8-on-report-judge-likely-to-overturn-base-load-review\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SCANA -8% on report judge likely to overturn base load review</a></h4><ul><li>SCANA (<a href='https://seekingalpha.com/symbol/SCG' title='SCANA Corporation'>SCG</a> <font color='red'>-8.5%</font>) plunges following a <em>Post  and Courier</em> report that a South Carolina judge is expected to rule  that the 2007 Base Load Review Act, which allows the company's South Carolina Electric &amp;&nbsp;Gas utility to charge  customers for a pair of unfinished nuclear reactors, is  <a href=\"https://www.postandcourier.com/business/judge-expected-to-overturn-law-that-forced-customers-to-pay/article_f88beb4a-d60c-11e8-81a7-ffa25e55541a.html\" target=\"_blank\">unconstitutional</a>.</li><li>The decision would clear the way for SCE&amp;G&rsquo;s ~720K ratepayers to stop paying for the nuclear project, which was called off  last year after massive budget overruns and mounting delays, and could open the door for lawyers to argue that SCE&amp;G should refund  ratepayers for the $2B-plus they already have put into the  project.</li><li>The events could set off a financial domino effect that SCG  has said could push it toward insolvency: SCE&amp;G is on the hook for  just over half of the $9B cost of the unfinished reactors at the V.C. Summer nuclear  power plant, and could scuttle a deal to be purchased by Dominion Energy (<a href='https://seekingalpha.com/symbol/D' title='Dominion Energy, Inc.'>D</a> <font color='red'>-0.3%</font>).</li></ul><div class=\"tiny-share-widget\" data-id=\"3399361\" data-linked=\"SCANA -8% on report judge likely to overturn base load review\" data-tweet=\"$SCG $SCG $D - SCANA -8% on report judge likely to overturn base load review https://seekingalpha.com/news/3399361-scanaminus-8-on-report-judge-likely-to-overturn-base-load-review?source=tweet\" data-url=\"https://seekingalpha.com/news/3399361-scanaminus-8-on-report-judge-likely-to-overturn-base-load-review\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>38&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399359\" data-ts=\"1540232895\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMZN\" target=\"_blank\">AMZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399359-aws-ceo-also-wants-bloomberg-to-retract-spy-chip-story\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AWS CEO also wants Bloomberg to retract spy chip story</a></h4><ul><li>        Amazon (<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a> <font color='green'>+1.1%</font>) Web Services CEO Andy Jassy <a href=\"https://twitter.com/ajassy/status/1054401346827243520?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E1054401346827243520&amp;ref_url=https%3A%2F%2Fwww.fastcompany.com%2F90254879%2Faws-ceo-joins-tim-cook-in-urging-bloomberg-to-retract-its-chinese-spy-story\" target=\"_blank\">tweets in support</a> of Apple CEO Tim Cook saying <i>Bloomberg Businessweek</i> should retract its report about malicious Chinese chips in Super Micro parts headed for U.S. tech and telecom giants.</li><li>                  Jassy&rsquo;s tweet: &ldquo;Tim Cook is right. Bloomberg story is wrong about Amazon, too. They offered no proof, story kept changing, and showed no interest in our answers unless we could validate their theories. Reporters got played or took liberties. Bloomberg should retract.&rdquo;    </li><li>               Amazon, Apple, Super Micro, U.S. telecoms, and China have denied (often repeatedly) the report&rsquo;s claims.&nbsp;</li><li>               Bloomberg stands by the story.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3398998-tim-cook-calls-bloomberg-retract-spy-chip-story\" target=\"_blank\">Tim Cook calls on Bloomberg to retract spy chip story</a> (Oct. 19)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3399157-super-micro-will-review-chips-featured-bloomberg-report\" target=\"_blank\">Super Micro will review chips featured in Bloomberg report</a> (Oct. 22)</li></ul><div class=\"tiny-share-widget\" data-id=\"3399359\" data-linked=\"AWS CEO also wants Bloomberg to retract spy chip story\" data-tweet=\"$AMZN - AWS CEO also wants Bloomberg to retract spy chip story https://seekingalpha.com/news/3399359-aws-ceo-also-wants-bloomberg-to-retract-spy-chip-story?source=tweet\" data-url=\"https://seekingalpha.com/news/3399359-aws-ceo-also-wants-bloomberg-to-retract-spy-chip-story\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399353\" data-ts=\"1540231915\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ANW\" target=\"_blank\">ANW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399353-aegean-marine-tops-energy-materials-sector-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aegean Marine tops Energy/Materials sector gainers</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ANW' title='Aegean Marine Petroleum Network Inc.'>OTC:ANW</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/KLXE' title='KLX Energy Services Holdings, Inc.'>KLXE</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/SMLP' title='Summit Midstream Partners'>SMLP</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/GGB' title='Gerdau S.A.'>GGB</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/SDPI' title='Superior Drilling Products, Inc.'>SDPI</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/IGC' title='India Globalization Capital, Inc'>OTC:IGC</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/PVL' title='Enduro Royalty Shs of Benef Interest'>PVL</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/TGA' title='Transglobe Energy Corp'>TGA</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/RCON' title='Recon Technology, Ltd.'>RCON</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/SES' title='Synthesis Energy Systems, Inc.'>SES</a> <font color='red'>-12%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3399353\" data-linked=\"Aegean Marine tops Energy/Materials sector gainers\" data-tweet=\"$ANW $ANW $KLXE - Aegean Marine tops Energy/Materials sector gainers https://seekingalpha.com/news/3399353-aegean-marine-tops-energy-materials-sector-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3399353-aegean-marine-tops-energy-materials-sector-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:11 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399352\" data-ts=\"1540231877\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRVS\" target=\"_blank\">CRVS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399352-corvus-up-1-on-encouraging-biomarker-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Corvus up 1% on encouraging biomarker data</a></h4><ul><li>Thinly traded micro cap Corvus Pharmaceuticals (<a href='https://seekingalpha.com/symbol/CRVS' title='Corvus Pharmaceuticals'>CRVS</a> <font color='green'>+1.4%</font>) is up on below-average volume on the heels of its <a href=\"https://seekingalpha.com/pr/17307230-corvus-pharmaceuticals-announces-new-data-adenosine-gene-signature-biomarker-associated\" target=\"_blank\">announcement </a>of new data on a biomarker associated with patient response to <a href=\"https://www.corvuspharma.com/pipeline/our-products/\" target=\"_blank\">CPI-444</a>, an adenosine A2A receptor antagonist. The results were presented as ESMO in Munich.</li><li>The company calls the biomarker \"adenosine gene signature\" and says the data show that CPI-444 in&nbsp;immune cells blocks this gene expression which confirms its mechanism of action.</li><li>The company adds that CPI-444 will be an effective add-on therapy to PD-1/L1 inhibitors since tumors with an adenosine-rich environment are resistant to them.</li><li>#ESMO</li></ul><div class=\"tiny-share-widget\" data-id=\"3399352\" data-linked=\"Corvus up 1% on encouraging biomarker data\" data-tweet=\"$CRVS - Corvus up 1% on encouraging biomarker data https://seekingalpha.com/news/3399352-corvus-up-1-on-encouraging-biomarker-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3399352-corvus-up-1-on-encouraging-biomarker-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:11 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399349\" data-ts=\"1540230858\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FB\" target=\"_blank\">FB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399349-pipers-fall-survey-instagram-beats-snap-in-teen-use\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Piper&#39;s fall survey: Instagram beats Snap in teen use</a></h4><ul><li>        Piper Jaffray says Instagram (<a href='https://seekingalpha.com/symbol/FB' title='Facebook'>FB</a> <font color='green'>+0.6%</font>) <a href=\"https://www.cnbc.com/2018/10/22/instagram-ahead-of-snapchat-in-popularity-among-teens-piper-jaffray.html\" target=\"_blank\">comes out ahead</a> of Snapchat (<a href='https://seekingalpha.com/symbol/SNAP' title='Snap Inc.'>SNAP</a> <font color='red'>-0.1%</font>) in popularity with teenagers.&nbsp;</li><li>               The firm&rsquo;s fall 2019 survey found 85% of teens use Instagram at least once a month while 84% use former market leader Snapchat. Instagram gained 3 percentage points since the spring survey while Snapchat gained 1 point.&nbsp;</li><li>               Twitter came in third with 47%, down from 53% in the Spring. Facebook also fell between the surveys, from 53% to 47%.&nbsp;</li><li>               When teens were asked to name their favorite social platform, Snapchat stays in the lead with 46% (-1 point from spring) followed by Instagram at 32% (+6), Twitter at 6% (-3), and Facebook at 5% (-3).&nbsp;</li><li>               Other survey leaders: Amazon (<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a> <font color='green'>+1.2%</font>) as the favorite website, Netflix (<a href='https://seekingalpha.com/symbol/NFLX' title='Netflix, Inc.'>NFLX</a> <font color='red'>-1.1%</font>) as the top streaming service with teens spending 38% of each day watching, and Nike (<a href='https://seekingalpha.com/symbol/NKE' title='Nike Inc.'>NKE</a> <font color='green'>+1.1%</font>) as the top retail store.&nbsp;</li><li>                  The survey included 8,600 teens across the United States with an average age of 16.&nbsp; </li></ul><div class=\"tiny-share-widget\" data-id=\"3399349\" data-linked=\"Piper&#39;s fall survey: Instagram beats Snap in teen use\" data-tweet=\"$FB $FB $SNAP - Piper&#39;s fall survey: Instagram beats Snap in teen use https://seekingalpha.com/news/3399349-pipers-fall-survey-instagram-beats-snap-in-teen-use?source=tweet\" data-url=\"https://seekingalpha.com/news/3399349-pipers-fall-survey-instagram-beats-snap-in-teen-use\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:54 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399348\" data-ts=\"1540230695\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HAS\" target=\"_blank\">HAS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399348-hasbro-pares-loss-after-conference-call\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hasbro pares loss after conference call</a></h4><ul> <li>Shares of Hasbro (<a href='https://seekingalpha.com/symbol/HAS' title='Hasbro, Inc.'>HAS</a> <font color='red'>-3.4%</font>) came off their lows after CEO Brian Goldner said on the company's conference call that approximately $50M worth of U.S. Q3 orders shipped out in the first week of Q4.</li> <li>Other positives from the CC were the upside seen on Fortnite nerf toys and the low exposure of Hasbro to Sears (less than 1% of sales).</li> <li><a href=\"https://seekingalpha.com/article/4213118-hasbro-inc-2018-q3-results-earnings-call-slides\" target=\"_blank\">Hasbro earnings call slides</a> (.pdf)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3399124-hasbro-minus-5-percent-sales-fall-back\" target=\"_blank\">Hasbro -5% as sales fall back</a> (Oct. 22)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3399348\" data-linked=\"Hasbro pares loss after conference call\" data-tweet=\"$HAS - Hasbro pares loss after conference call https://seekingalpha.com/news/3399348-hasbro-pares-loss-after-conference-call?source=tweet\" data-url=\"https://seekingalpha.com/news/3399348-hasbro-pares-loss-after-conference-call\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:51 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399345\" data-ts=\"1540230372\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EXEL\" target=\"_blank\">EXEL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399345-exelixis-down-3-on-cabometyx-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Exelixis down 3% on Cabometyx data</a></h4><ul><li>Results from the dose escalation portion of a Phase 1b clinical trial, COSMIC-021, evaluating Exelixis' (<a href='https://seekingalpha.com/symbol/EXEL' title='Exelixis, Inc.'>EXEL</a> <font color='red'>-3.4%</font>) CABOMETYX (cabozantinib), combined with Roche's (<a href='https://seekingalpha.com/symbol/RHHBY' title='Roche Holding Ltd ADR'>OTCQX:RHHBY</a> <font color='green'>+0.1%</font>) TECENTRIQ (atezolizumab), in treatment-naive patients with advanced renal cell carcinoma &#40;RCC&#41;&nbsp;showed encouraging action. The data were presented at ESMO in Munich.</li><li>12 patients were treated, 10 with clear cell RCC and two with non-clear cell RCC. The response rate in clear cell RCC was 80% (n=8/10), but 0% in non-clear RCC. The disease control rate (responders + stable disease) was 100% (n=12/12) for the group.</li><li>The Grade 3 (serious) adverse event rate was 83% in the 40 mg cabozantinib cohort, the most frequent being hypertension (50%).</li><li>#ESMO</li></ul><div class=\"tiny-share-widget\" data-id=\"3399345\" data-linked=\"Exelixis down 3% on Cabometyx data\" data-tweet=\"$EXEL $EXEL $RHHBY - Exelixis down 3% on Cabometyx data https://seekingalpha.com/news/3399345-exelixis-down-3-on-cabometyx-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3399345-exelixis-down-3-on-cabometyx-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>28&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399346\" data-ts=\"1540230061\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/YNDX\" target=\"_blank\">YNDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399346-yandex-considers-restructuring-russian-law-passes\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Yandex considers restructuring if Russian law passes</a></h4><ul><li>           Yandex (NASDAQ:<a href='https://seekingalpha.com/symbol/YNDX' title='Yandex N.V.'>YNDX</a>) is <a href=\"https://www.reuters.com/article/russia-yandex/yandex-mulls-restructuring-news-services-to-comply-with-proposed-law-on-foreign-ownership-idUSR4N1WX01Y?feedType=RSS&amp;feedName=companyNews&amp;utm_source=feedburner&amp;utm_medium=feed&amp;utm_campaign=Feed%3A+reuters%2FcompanyNews+%28News+%2F+US+%2F+Company+News%29\" target=\"_blank\">considering restructuring</a> its news service to be compliant with a proposed law that would limit foreign ownership of news aggregators in Russia. </li><li>           The draft law would limit foreign investors from owning an over 20% stake in local news aggregators. The law has been sent to parliament.  </li><li> Yandex&rsquo;s parent company is registered in the Netherlands. </li><li> Yandex shares are&nbsp;<font color='green'>up 1%</font>&nbsp;to $27.68.&nbsp; </li></ul><div class=\"tiny-share-widget\" data-id=\"3399346\" data-linked=\"Yandex considers restructuring if Russian law passes\" data-tweet=\"$YNDX - Yandex considers restructuring if Russian law passes https://seekingalpha.com/news/3399346-yandex-considers-restructuring-russian-law-passes?source=tweet\" data-url=\"https://seekingalpha.com/news/3399346-yandex-considers-restructuring-russian-law-passes\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:41 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399340\" data-ts=\"1540229469\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BGNE\" target=\"_blank\">BGNE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399340-beigene-down-5-on-parp-inhibitor-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BeiGene down 5% on PARP inhibitor data</a></h4><ul><li>BeiGene (<a href='https://seekingalpha.com/symbol/BGNE' title='BeiGene'>BGNE</a> <font color='red'>-4.5%</font>) is down on below-average volume on the heels of its <a href=\"https://seekingalpha.com/pr/17306983-beigene-presents-preliminary-clinical-data-parp-inhibitor-pamiparib-combination-low-dose\" target=\"_blank\">announcement </a>of preliminary data from a Phase 1 clinical trial evaluating PARP inhibitor pamiparib, combined with low-dose chemo agent temozolomide, in patients with locally advanced/metastatic solid tumors. The results were presented at ESMO in Munich.</li><li>40 patients were enrolled as of late August with a median of four prior lines of therapy. Median duration of treatment was 1.6 months. At data cutoff, 18 remained on treatment.</li><li>23 patients with solid tumors other than prostate cancer were evaluable. The confirmed response rate was 9% (n=2/23). The disease control rate &#40;DCR&#41; (responders + stable disease) was 52% (n=12/23).</li><li>In seven prostate cancer patients, the confirmed response rate was 14% (n=1/7) with a DCR of 29% (n=2/7).</li><li>Development is ongoing.</li><li>#ESMO</li></ul><div class=\"tiny-share-widget\" data-id=\"3399340\" data-linked=\"BeiGene down 5% on PARP inhibitor data\" data-tweet=\"$BGNE - BeiGene down 5% on PARP inhibitor data https://seekingalpha.com/news/3399340-beigene-down-5-on-parp-inhibitor-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3399340-beigene-down-5-on-parp-inhibitor-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:31 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399337\" data-ts=\"1540228729\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ROYL\" target=\"_blank\">ROYL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399337-royale-signs-joint-venture-to-expand-drilling-in-rio-vista-field\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Royale signs joint venture to expand drilling in Rio Vista Field</a></h4><ul>     <li>Royale Energy (<a href='https://seekingalpha.com/symbol/ROYL' title='Royale Energy, Inc.'>OTC:ROYL</a> <font color='green'>+14.3%</font>) has <a href=\"https://seekingalpha.com/pr/17307656-royale-signs-joint-venture-expand-drilling-rio-vista-field\" target=\"_blank\">entered into a joint venture</a> with California Resources Corporation (<a href='https://seekingalpha.com/symbol/CRC' title='California Resources Corporation'>CRC</a> <font color='red'>-2.4%</font>) to drill 30 wells throughout the Rio Vista field.</li>     <li>The Rio Vista field was discovered in 1936 and has produced ~4 trillion cubic ft. from more than 15 stacked gas reservoirs.</li>     <li>The said new agreement expands the JV development area to the entire Rio Vista field.</li>      </ul><div class=\"tiny-share-widget\" data-id=\"3399337\" data-linked=\"Royale signs joint venture to expand drilling in Rio Vista Field\" data-tweet=\"$ROYL $ROYL $CRC - Royale signs joint venture to expand drilling in Rio Vista Field https://seekingalpha.com/news/3399337-royale-signs-joint-venture-to-expand-drilling-in-rio-vista-field?source=tweet\" data-url=\"https://seekingalpha.com/news/3399337-royale-signs-joint-venture-to-expand-drilling-in-rio-vista-field\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399336\" data-ts=\"1540228217\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MSC\" target=\"_blank\">MSC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399336-studio-cityplus-10-in-week-two-of-trading\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Studio City +10% in week two of trading</a></h4><ul> <li>Studio City International Holdings (NYSE:<a href='https://seekingalpha.com/symbol/MSC' title='Studio City International Holdings'>MSC</a>) is <font color='green'>up 10.2%</font> amid a solid day for Macau casino stocks in general.</li> <li>The post-IPO high for Studio City is $18.49 after the offering was priced at $12.50 last week.</li><li>Analysts are in a quiet period on Studio City, but Seeking Alpha contributors are&nbsp;<a href=\"https://seekingalpha.com/symbol/MSC\" target=\"_blank\">sizing up</a> the Macau pure play.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3399336\" data-linked=\"Studio City +10% in week two of trading\" data-tweet=\"$MSC $MLCO - Studio City +10% in week two of trading https://seekingalpha.com/news/3399336-studio-cityplus-10-in-week-two-of-trading?source=tweet\" data-url=\"https://seekingalpha.com/news/3399336-studio-cityplus-10-in-week-two-of-trading\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:10 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399335\" data-ts=\"1540227846\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UNFI\" target=\"_blank\">UNFI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399335-united-natural-foods-closes-on-supervalu-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">United Natural Foods closes on Supervalu deal</a></h4><ul> <li>United Natural Foods (<a href='https://seekingalpha.com/symbol/UNFI' title='United Natural Foods, Inc.'>UNFI</a> <font color='red'>-9%</font>) discloses that the company closed on the $2.9B acquisition of Supervalu (<a href='https://seekingalpha.com/symbol/SVU' title='SUPERVALU Inc.'>SVU</a>).</li><li>\"We will take the best from both businesses to create North America's premier food wholesaler with significant scale, reach and choices for our customers,\" says United Natural Foods CEO Steve Spinner.</li><li>UNFI projects run-rate cost synergies associated with this transaction of more than $175M&nbsp;by year three and more than $185M by year four. The company says it's committed to improving profitability into the future by leveraging scalable systems to streamline processes and by reducing future capital expenditures.</li><li>An update on integration efforts is planned for the company's investor day event on January 16.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17307435-unfi-completes-transformative-acquisition-supervalu\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3399335\" data-linked=\"United Natural Foods closes on Supervalu deal\" data-tweet=\"$UNFI $UNFI $SVU - United Natural Foods closes on Supervalu deal https://seekingalpha.com/news/3399335-united-natural-foods-closes-on-supervalu-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3399335-united-natural-foods-closes-on-supervalu-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399333\" data-ts=\"1540227546\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LNMIF\" target=\"_blank\">LNMIF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399333-lonmin-wins-200m-china-loan-deal-ahead-of-sibanye-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lonmin wins $200M China loan deal ahead of Sibanye deal</a></h4><ul>     <li>Struggling platinum miner Lonmin (<a href='https://seekingalpha.com/symbol/LNMIF' title='Lonmin plc'>OTC:LNMIF</a>) says it <a href=\"http://www.mining.com/lonmin-200m-loan-deal-state-backed-chinese-company/\" target=\"_blank\">raised $200M</a> through a metal-for-loan deal with a Chinese state-backed company, providing improved liquidity as it awaits the closure of Sibanye-Stillwater's (<a href='https://seekingalpha.com/symbol/SBGL' title='Sibanye-Stillwater'>SBGL</a> <font color='red'>-2.5%</font>) takeover of the company.</li>     <li>Under the deal, Lonmin will repay most of the loan by delivering platinum and palladium over three years to a subsidiary of Jiangxi Copper, China&rsquo;s top copper producer.</li>     <li>Lonmin also says it will settle its $150M pre-existing term loan and cancel its other pre-existing undrawn facilities with both its South African rand and U.S. dollar lender groups.</li>     <li>Lonmin still expects to release 3,700 employees before the end of the year.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3399333\" data-linked=\"Lonmin wins $200M China loan deal ahead of Sibanye deal\" data-tweet=\"$LNMIF $LNMIF $SBGL - Lonmin wins $200M China loan deal ahead of Sibanye deal https://seekingalpha.com/news/3399333-lonmin-wins-200m-china-loan-deal-ahead-of-sibanye-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3399333-lonmin-wins-200m-china-loan-deal-ahead-of-sibanye-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>73&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399331\" data-ts=\"1540227380\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JTPY\" target=\"_blank\">JTPY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399331-jetpay-corp-tops-financial-sector-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jetpay Corp tops financial sector gainers</a></h4><ul><li><b>Gainers:&nbsp;</b><a href='https://seekingalpha.com/symbol/JTPY' title='JetPay Corporation'>JTPY</a> <font color='green'>+142%</font>. <a href='https://seekingalpha.com/symbol/LX' title='LexinFintech Holdings Ltd. ADS'>LX</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/OXBR' title='Oxbridge Re Holdings Limited'>OXBR</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/YIN' title='Yintech Investment Holdings'>YIN</a> <font color='green'>+6%</font>.</li><li><b>Losers: </b><a href='https://seekingalpha.com/symbol/OPB' title='Opus Bank'>OPB</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/LYL' title='Dragon Victory International Limited'>LYL</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/CIFS' title='China Internet Nationwide Financial Services Inc.'>CIFS</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/OPHC' title='OptimumBank Holdings, Inc.'>OPHC</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/AINC' title='Ashford Inc.'>AINC</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3399331\" data-linked=\"Jetpay Corp tops financial sector gainers\" data-tweet=\"$JTPY $JTPY $LX - Jetpay Corp tops financial sector gainers https://seekingalpha.com/news/3399331-jetpay-corp-tops-financial-sector-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3399331-jetpay-corp-tops-financial-sector-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:56 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399329\" data-ts=\"1540226987\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ESEA\" target=\"_blank\">ESEA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399329-shipping-and-biotech-top-list-of-midday-movers-10-22-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Shipping and Biotech top list of midday movers (10/22/2018)</a></h4><ul>     <li><strong>Gainers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/ESEA' title='Euroseas Ltd.'>ESEA</a> <font color='green'>+173%</font>. <a href='https://seekingalpha.com/symbol/JTPY' title='JetPay Corporation'>JTPY</a> <font color='green'>+142%</font>. <a href='https://seekingalpha.com/symbol/TOPS' title='TOP Ships Inc.'>TOPS</a> <font color='green'>+108%</font>. <a href='https://seekingalpha.com/symbol/NETE' title='Net Element International, Inc.'>NETE</a> <font color='green'>+64%</font>. <a href='https://seekingalpha.com/symbol/GLBS' title='Globus Maritime Ltd.'>GLBS</a> <font color='green'>+54%</font>. <a href='https://seekingalpha.com/symbol/ARII' title='American Railcar Industries, Inc.'>ARII</a> <font color='green'>+51%</font>. <a href='https://seekingalpha.com/symbol/DCIX' title='Diana Containerships Inc.'>DCIX</a> <font color='green'>+50%</font>. <a href='https://seekingalpha.com/symbol/PXS' title='Pyxis Tankers Inc.'>PXS</a> <font color='green'>+40%</font>. <a href='https://seekingalpha.com/symbol/SINO' title='Sino-Global Shipping America, Ltd.'>SINO</a> <font color='green'>+35%</font>. <a href='https://seekingalpha.com/symbol/NVMM' title='NOVUME SOLUTIONS INC'>NVMM</a> <font color='green'>+32%</font>.</li>     <li><strong>Losers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/PLAG' title='Planet Green Holdings Corp'>PLAG</a> <font color='red'>-58%</font>. <a href='https://seekingalpha.com/symbol/ADRO' title='Aduro Biotech'>ADRO</a> <font color='red'>-36%</font>. <a href='https://seekingalpha.com/symbol/ADAP' title='Adaptimmune Therapeutics plc'>ADAP</a> <font color='red'>-28%</font>. <a href='https://seekingalpha.com/symbol/CCCL' title='China Ceramics Co., Ltd.'>CCCL</a> <font color='red'>-23%</font>. <a href='https://seekingalpha.com/symbol/YGYI' title='Youngevity International, Inc.'>YGYI</a> <font color='red'>-23%</font>. <a href='https://seekingalpha.com/symbol/CLVS' title='Clovis Oncology'>CLVS</a> <font color='red'>-21%</font>. <a href='https://seekingalpha.com/symbol/NCTY' title='The9 Limited'>NCTY</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/YECO-OLD' title='Yulong Eco-Materials'>YECO-OLD</a> <font color='red'>-21%</font>. <a href='https://seekingalpha.com/symbol/ABIL' title='Ability Inc.'>ABIL</a> <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/CNET' title='ChinaNet Online Holdings, Inc.'>CNET</a> <font color='red'>-19%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3399329\" data-linked=\"Shipping and Biotech top list of midday movers (10/22/2018)\" data-tweet=\"$ESEA $ESEA $JTPY - Shipping and Biotech top list of midday movers (10/22/2018) https://seekingalpha.com/news/3399329-shipping-and-biotech-top-list-of-midday-movers-10-22-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3399329-shipping-and-biotech-top-list-of-midday-movers-10-22-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399328\" data-ts=\"1540226764\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RIG\" target=\"_blank\">RIG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399328-transocean-wins-new-contracts-fleet-status-report-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Transocean wins new contracts, fleet status report says</a></h4><ul>     <li>Transocean's (<a href='https://seekingalpha.com/symbol/RIG' title='Transocean Ltd.'>RIG</a> <font color='red'>-2.2%</font>) latest <a href=\"https://seekingalpha.com/pr/17306889-transocean-ltd-provides-quarterly-fleet-status-report\" target=\"_blank\">fleet status report</a> shows further contract awards amid a market recovery, highlighted by a new contract for a currently idle drillship to begin work offshore China.</li>     <li>RIG reports its <em>Dhirubhai Deepwater KG2</em> drillship won a three-well contract with China's CNOOC, which is expected to start in February 2019 and end in June 2019; the contract also includes plus two one-well options.</li>     <li>RIG also says the <em>Henry Goodrich</em> semi-submersible drilling rig was awarded a one-year contract extension with Husky energy offshore eastern Canada with a $275K dayrate, set to end in November 2019.</li>     <li>The Transocean Leader semi-submersible rig was awarded a three-well contract in the U.K. North Sea by Hurricane Energy, and the Paul B. Loyd, Jr. semi-submersible rig was awarded a two-well contract by&nbsp;BP; dayrates were not disclosed.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3399328\" data-linked=\"Transocean wins new contracts, fleet status report says\" data-tweet=\"$RIG - Transocean wins new contracts, fleet status report says https://seekingalpha.com/news/3399328-transocean-wins-new-contracts-fleet-status-report-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3399328-transocean-wins-new-contracts-fleet-status-report-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399326\" data-ts=\"1540226139\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KURA\" target=\"_blank\">KURA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399326-kura-down-14-on-modest-hnscc-scc-potential-for-tipifarnib\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kura down 14% on modest HNSCC/SCC potential for tipifarnib</a></h4><ul><li>Results from a Phase 2 clinical trial evaluating Kura Oncology's (<a href='https://seekingalpha.com/symbol/KURA' title='Kura Oncology'>KURA</a> <font color='red'>-14.1%</font>) lead candidate tipifarnib in patients with HRAS-positive squamous cell carcinomas &#40;SCC&#41;&nbsp;showed a positive effect that appears to disappoint investors. The data were presented at ESMO in Munich.</li><li>The confirmed response rate in 17 patients with HRAS+ head and neck squamous cell carcinomas &#40;HNSCC&#41; was 35% (n=6/17). The disease control rate &#40;DCR&#41; (responders + stable cancer) was 59% (n=10/17). The response rate was 46% (n=6/13) in HNSCC/SCC patients with HRAS mutant allele frequency greater than 20% with a DCR of 62% (n=8/13).</li><li>No meaningful clinical benefit was observed in patients with an HRAS mutant allele frequency less than 20%, a patient population representing 95% of the overall HNSCC population.</li><li>#ESMO</li></ul><div class=\"tiny-share-widget\" data-id=\"3399326\" data-linked=\"Kura down 14% on modest HNSCC/SCC potential for tipifarnib\" data-tweet=\"$KURA - Kura down 14% on modest HNSCC/SCC potential for tipifarnib https://seekingalpha.com/news/3399326-kura-down-14-on-modest-hnscc-scc-potential-for-tipifarnib?source=tweet\" data-url=\"https://seekingalpha.com/news/3399326-kura-down-14-on-modest-hnscc-scc-potential-for-tipifarnib\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399325\" data-ts=\"1540225783\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NM\" target=\"_blank\">NM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399325-investors-bid-up-shipping-stocks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Investors bid up shipping stocks</a></h4><ul> <li>Shipping stocks are higher on the day after the Baltic Dry Index shows a gain for the third consecutive day. The index currently stands at 1,576 vs. the 52-week trading range of $948 to $1,774.</li>  <li>A +4% surge in Chinese stocks today earlier is also providing a big sentiment lift for shipping stocks trading in the U.S.</li><li>Finally, the withdrawal of the U.S. from the Universal Post Union is seen as supportive of international shipping rates across categories.</li> <li>Shipping and tanker gainers off the mix of news include Navios Maritime (<a href='https://seekingalpha.com/symbol/NM' title='Navios Maritime Holdings Inc.'>NM</a> <font color='green'>+17.8%</font>), Dry Ships (<a href='https://seekingalpha.com/symbol/DRYS' title='DryShips Inc.'>DRYS</a> <font color='green'>+14.7%</font>), Navios Maritime Acquisition (<a href='https://seekingalpha.com/symbol/NNA' title='Navios Maritime Acquisition Corporation'>NNA</a> <font color='green'>+7.7%</font>), Euroseas (<a href='https://seekingalpha.com/symbol/ESEA' title='Euroseas Ltd.'>ESEA</a> <font color='green'>+143.2%</font>), EuroSry (<a href='https://seekingalpha.com/symbol/EDRY' title='EuroDry Ltd.'>EDRY</a> <font color='green'>+18.3%</font>), Seanergy Maritime (<a href='https://seekingalpha.com/symbol/SHIP' title='Seanergy Maritime Holdings Corp'>SHIP</a> <font color='green'>+22.8%</font>), Global Ship Lease (<a href='https://seekingalpha.com/symbol/GSL' title='Global Ship Lease, Inc'>GSL</a> <font color='green'>+15%</font>), Danaos (<a href='https://seekingalpha.com/symbol/DAC' title='Danaos Corporation'>DAC</a> <font color='green'>+14.4%</font>), Globus Maritime (<a href='https://seekingalpha.com/symbol/GLBS' title='Globus Maritime Ltd.'>GLBS</a> <font color='green'>+47.2%</font>), TOP Ships (<a href='https://seekingalpha.com/symbol/TOPS' title='TOP Ships Inc.'>TOPS</a> <font color='green'>+90.6%</font>), Eagle Bulk Shipping (<a href='https://seekingalpha.com/symbol/EGLE' title='Eagle Bulk Shipping Inc.'>EGLE</a> <font color='green'>+8.4%</font>) and Diana Shipping (<a href='https://seekingalpha.com/symbol/DSX' title='Diana Shipping, Inc.'>DSX</a> <font color='green'>+3.7%</font>).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3399325\" data-linked=\"Investors bid up shipping stocks\" data-tweet=\"$NM $NM $DRYS - Investors bid up shipping stocks https://seekingalpha.com/news/3399325-investors-bid-up-shipping-stocks?source=tweet\" data-url=\"https://seekingalpha.com/news/3399325-investors-bid-up-shipping-stocks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399324\" data-ts=\"1540225687\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LUXTY\" target=\"_blank\">LUXTY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399324-luxottica-group-reports-q3-sales\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Luxottica Group reports Q3 sales</a></h4><ul>     <li>Luxottica (<a href='https://seekingalpha.com/symbol/LUXTY' title='Luxottica Group, S.p.a. ADR'>OTCPK:LUXTY</a> <font color='red'>-3.6%</font>) reports Q3 sales of&nbsp;&euro;2.215B (+3.5% Y/Y).</li>     <li>Wholesale division&rsquo;s net sales were &euro;732M: +0.9% at constant exchange rates and -1.0% at current exchange rates.</li>     <li>Retail division&rsquo;s net sales were &euro;1.483B: +4.8% at constant exchange rates and +4.9% at current exchange rates.</li><li><a href=\"http://www.luxottica.com/en/third-quarter-net-sales-grow-35-driven-retail-and-commerce\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3399324\" data-linked=\"Luxottica Group reports Q3 sales\" data-tweet=\"$LUXTY - Luxottica Group reports Q3 sales https://seekingalpha.com/news/3399324-luxottica-group-reports-q3-sales?source=tweet\" data-url=\"https://seekingalpha.com/news/3399324-luxottica-group-reports-q3-sales\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399323\" data-ts=\"1540225481\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399323-tech-lunch-break-semis-rebound-on-positive-bofaml-note\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tech lunch break: Semis rebound on positive BofAML note</a></h4><ul><li>The Technology Select Sector SPDR Fund (NYSEARCA:<a href='https://seekingalpha.com/symbol/XLK' title='Technology Select Sector SPDR ETF'>XLK</a>) is&nbsp;<font color='green'>up 0.81%,&nbsp;</font>the S&amp;P 500 IT Index is&nbsp;<font color='green'>up 0.78%</font>, and the Philadelphia Semiconductor Index&nbsp;<font color='green'>up 0.2%</font>&nbsp;compared to the<font color='red'>&nbsp;0.4%</font>&nbsp;drop for the S&amp;P 500.</li><li>Semi: Semiconductors gain as two AMD&nbsp;<font color='green'>+4.9%</font>&nbsp;target boosts and a positive BofAML note on the sector overcome Micron&nbsp;<font color='red'>-1.7%</font>&nbsp;weakness after a Raymond James initiation.</li><li>Industrial laser stocks are down after Coherent&nbsp;<font color='red'>-7.2%&nbsp;</font>provided lower Q4 preliminary results partly on Chinese weakness, which led to B. Riley coming out cautious on II-VI&nbsp;<font color='red'>-2.1%&nbsp;</font>and Fabrinet&nbsp;<font color='red'>-1.2%</font>.</li><li>Earnings after close: Cadence Design Systems&nbsp;<font color='green'>+1%</font>, Logitech&nbsp;<font color='green'>+1.7%</font>.</li><li>Earnings before tomorrow's open: Verizon, Corning.</li><li>Related semiconductor ETFs: <a href='https://seekingalpha.com/symbol/SOXL' title='Direxion Daily Semiconductor 3x Bull Shares ETF'>SOXL</a>, <a href='https://seekingalpha.com/symbol/SOXX' title='iShares PHLX SOX Semiconductor Sector Index ETF'>SOXX</a>, <a href='https://seekingalpha.com/symbol/SMH' title='VanEck Vectors Semiconductor ETF'>SMH</a>, <a href='https://seekingalpha.com/symbol/USD' title='ProShares Ultra Semiconductors ETF'>USD</a>, <a href='https://seekingalpha.com/symbol/PSI' title='Invesco Dynamic Semiconductors Portfolio ETF'>PSI</a>, <a href='https://seekingalpha.com/symbol/XSD' title='SPDR S&P Semiconductor ETF'>XSD</a>, <a href='https://seekingalpha.com/symbol/SOXS' title='Direxion Daily Semiconductor 3x Bear Shares ETF'>SOXS</a>, <a href='https://seekingalpha.com/symbol/SSG' title='ProShares UltraShort Semiconductors ETF'>SSG</a>, <a href='https://seekingalpha.com/symbol/FTXL' title='First Trust Nasdaq Semiconductor ETF'>FTXL</a>, <a href='https://seekingalpha.com/symbol/XTH' title='SPDR S&P Technology Hardware ETF'>XTH</a></li><li>Today's top stories:</li><li>Previously: <a href=\"https://seekingalpha.com/news/3399311-b-riley-cautious-ii-vi-fabrinet-coherent-drop\" target=\"_blank\">B. Riley cautious on II-VI, Fabrinet after Coherent drop</a> (Oct. 22)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3399284-coherent-dips-6_7-percent-lower-preliminary-q4-results\" target=\"_blank\">Coherent dips 6.7% on lower preliminary Q4 results</a> (Oct. 22)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3399150-nomura-says-buy-intel-update\" target=\"_blank\">Nomura says Buy to Intel (update)</a> (Oct. 22)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3399315-amd-plus-6_4-percent-two-target-boosts\" target=\"_blank\">AMD +6.4% after two target boosts</a> (Oct. 22)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3399305-raymond-james-resumes-micron-market-perform\" target=\"_blank\">Raymond James resumes Micron at Market Perform</a> (Oct. 22)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3399306-bofaml-semi-correction-normal-buy\" target=\"_blank\">BofAML: Semi correction normal, here's what to buy</a> (Oct. 22)</li></ul><div class=\"tiny-share-widget\" data-id=\"3399323\" data-linked=\"Tech lunch break: Semis rebound on positive BofAML note\" data-tweet=\"$XLK $SOXL $SOXX - Tech lunch break: Semis rebound on positive BofAML note https://seekingalpha.com/news/3399323-tech-lunch-break-semis-rebound-on-positive-bofaml-note?source=tweet\" data-url=\"https://seekingalpha.com/news/3399323-tech-lunch-break-semis-rebound-on-positive-bofaml-note\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:24 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399319\" data-ts=\"1540224657\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGEN\" target=\"_blank\">AGEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399319-agenus-down-7-on-pdminus-1-ctlaminus-4-program-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Agenus down 7% on PD-1/CTLA-4 program data</a></h4><ul><li>Agenus (<a href='https://seekingalpha.com/symbol/AGEN' title='Agenus'>AGEN</a> <font color='red'>-6.6%</font>) is down on below-average volume following the <a href=\"https://seekingalpha.com/pr/17306670-agenus-presents-clinical-data-pdminus-1-and-ctlaminus-4-esmo-2018\" target=\"_blank\">presentation </a>of clinical data at ESMO on anti-PD-l antibody AGEN2034 and anti-CTLA-4 antibody AGEN1884.</li><li>The disease control rate &#40;DCR&#41;&nbsp;(responders + stable cancer) was 68% (n=52/76) in patients with advanced/metastatic solid tumors receiving AGEN2034, although the specific response rate is not provided.</li><li>The DCR in the combo arm was 44% (n=7/16) which appears to include one responder.</li><li>The company has a steep hill to climb to compete with Bristol-Myers Squibb's PD-1/CTLA-4 combo of Opdivo + Yervoy.</li><li>#ESMO</li></ul><div class=\"tiny-share-widget\" data-id=\"3399319\" data-linked=\"Agenus down 7% on PD-1/CTLA-4 program data\" data-tweet=\"$AGEN - Agenus down 7% on PD-1/CTLA-4 program data https://seekingalpha.com/news/3399319-agenus-down-7-on-pdminus-1-ctlaminus-4-program-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3399319-agenus-down-7-on-pdminus-1-ctlaminus-4-program-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399317\" data-ts=\"1540224409\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DFBG-OLD\" target=\"_blank\">DFBG-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399317-differential-brands-leads-consumer-gainers-losers-include-beverage-stocks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Differential Brands leads consumer gainers, losers include beverage stocks</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/DFBG-OLD' title='Differential Brands Group Inc.'>DFBG-OLD</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/FNKO' title='Funko, Inc.'>FNKO</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/TOUR' title='Tuniu Corporation'>TOUR</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/SAM' title='Boston Beer Co.'>SAM</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/CROX' title='Crocs, Inc.'>CROX</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/PLAG' title='Planet Green Holdings Corp'>PLAG</a> <font color='red'>-21%</font>. <a href='https://seekingalpha.com/symbol/YGYI' title='Youngevity International, Inc.'>YGYI</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/FTFT' title='Future Fintech Group Inc'>FTFT</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/PETZ' title='TDH Holdings, Inc.'>PETZ</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/NBEV' title='New Age Beverages Corporation'>NBEV</a> <font color='red'>-13%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3399317\" data-linked=\"Differential Brands leads consumer gainers, losers include beverage stocks\" data-tweet=\"$DFBG-OLD $DFBG-OLD $FNKO - Differential Brands leads consumer gainers, losers include beverage stocks https://seekingalpha.com/news/3399317-differential-brands-leads-consumer-gainers-losers-include-beverage-stocks?source=tweet\" data-url=\"https://seekingalpha.com/news/3399317-differential-brands-leads-consumer-gainers-losers-include-beverage-stocks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:06 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399315\" data-ts=\"1540224050\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMD\" target=\"_blank\">AMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399315-amdplus-6_4-after-two-target-boosts\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AMD +6.4% after two target boosts</a></h4><ul><li>        UBS <a href=\"https://www.streetinsider.com/Analyst+PT+Change/AMD+%28AMD%29+PT+Raised+to+%2425+at+UBS/14726121.html\" target=\"_blank\">raises</a> its AMD (NASDAQ:<a href='https://seekingalpha.com/symbol/AMD' title='Advanced Micro Devices, Inc.'>AMD</a>) target from $17 to $25 while maintaining a Neutral rating.</li><li>               More action: BMO <a href=\"https://www.streetinsider.com/Analyst+Comments/AMD+%28AMD%29+PT+Raised+to+%2420+at+BMO+Capital%3B+Plenty+of+Worry+Into+Earnings/14726400.html\" target=\"_blank\">raises</a> its AMD target from $14 to $20 and maintains a Market Perform rating.&nbsp;</li><li>               AMD shares are&nbsp;<font color='green'>up 6.4%&nbsp;</font>to $25.18. Shares are&nbsp;<font color='red'>down 24%</font>&nbsp;in the past month as Intel started to recover from its 10nm delays, which had benefitted AMD. AMD shares are&nbsp;<font color='green'>up 42%</font>&nbsp;in the quarter and&nbsp;<font color='green'>130%&nbsp;</font>YTD. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3399150-nomura-says-buy-intel-update\" target=\"_blank\">Nomura says Buy to Intel (update)</a> (Oct. 22)</li></ul><div class=\"tiny-share-widget\" data-id=\"3399315\" data-linked=\"AMD +6.4% after two target boosts\" data-tweet=\"$AMD - AMD +6.4% after two target boosts https://seekingalpha.com/news/3399315-amdplus-6_4-after-two-target-boosts?source=tweet\" data-url=\"https://seekingalpha.com/news/3399315-amdplus-6_4-after-two-target-boosts\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>41&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399313\" data-ts=\"1540223470\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTAP\" target=\"_blank\">NTAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399313-netappplus-2_9-ahead-of-tomorrows-analyst-session\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NetApp +2.9% ahead of tomorrow&#39;s analyst session</a></h4><ul><li>        NetApp (NASDAQ:<a href='https://seekingalpha.com/symbol/NTAP' title='NetApp, Inc.'>NTAP</a>) gains ahead of <a href=\"https://seekingalpha.com/pr/17302670-netapp-hosts-technology-sessions-2018-insight-conference-las-vegas-nevada\" target=\"_blank\">tomorrow&rsquo;s</a> 2018 Insight conference in Las Vegas.</li><li>               The company&rsquo;s technology sessions for financial analysts will have a live webcast from 4 PM to 7:15 PM ET available <a href=\"http://investors.netapp.com/\" target=\"_blank\">here</a>.&nbsp;</li><li>               NetApp shares are&nbsp;<font color='green'>up 2.9%</font>&nbsp;to $79.82. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3399313\" data-linked=\"NetApp +2.9% ahead of tomorrow&#39;s analyst session\" data-tweet=\"$NTAP - NetApp +2.9% ahead of tomorrow&#39;s analyst session https://seekingalpha.com/news/3399313-netappplus-2_9-ahead-of-tomorrows-analyst-session?source=tweet\" data-url=\"https://seekingalpha.com/news/3399313-netappplus-2_9-ahead-of-tomorrows-analyst-session\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:51 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399308\" data-ts=\"1540223121\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IONS\" target=\"_blank\">IONS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399308-ionis-pharmas-danvatirsen-shows-positive-effect-in-mid-stage-head-and-neck-cancer-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ionis Pharma&#39;s danvatirsen shows positive effect in mid-stage head and neck cancer study; shares up 4%</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/17307283-phase-1b-2-data-durvalumab-plus-danvatirsen-presented-european-society-medical-oncology\" target=\"_blank\">Results </a>from a Phase 1b/2 clinical trial evaluating Ionis Pharmaceuticals' (<a href='https://seekingalpha.com/symbol/IONS' title='Ionis Pharmaceuticals, Inc.'>IONS</a> <font color='green'>+3.7%</font>) antisense drug danvatirsen (AZD9150), combined with AstraZeneca's (<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca Group plc'>AZN</a> <font color='green'>+0.4%</font>) PD-L1 inhibitor Imfinzi (durvalumab), in patients with recurrent metastatic head and neck cancer showed a treatment effect. The data were presented at ESMO in Munich.</li><li>Patients receiving the combo showed a response rate of 23%, including a 7% complete response rate, double the rate for durvalumab alone.</li><li>Advancement into Phase 2 triggered a $17.5M milestone payment to IONS from AZN.</li><li>#ESMO</li></ul><div class=\"tiny-share-widget\" data-id=\"3399308\" data-linked=\"Ionis Pharma&#39;s danvatirsen shows positive effect in mid-stage head and neck cancer study; shares up 4%\" data-tweet=\"$IONS $IONS $AZN - Ionis Pharma&#39;s danvatirsen shows positive effect in mid-stage head and neck cancer study; shares up 4% https://seekingalpha.com/news/3399308-ionis-pharmas-danvatirsen-shows-positive-effect-in-mid-stage-head-and-neck-cancer-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3399308-ionis-pharmas-danvatirsen-shows-positive-effect-in-mid-stage-head-and-neck-cancer-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399311\" data-ts=\"1540222986\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IIVI\" target=\"_blank\">IIVI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399311-b-riley-cautious-on-ii-vi-fabrinet-after-coherent-drop\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">B. Riley cautious on II-VI, Fabrinet after Coherent drop</a></h4><ul><li>        B. Riley is out cautious on II-VI (NASDAQ:<a href='https://seekingalpha.com/symbol/IIVI' title='II-VI Incorporated'>IIVI</a>) and Fabrinet (NYSE:<a href='https://seekingalpha.com/symbol/FN' title='Fabrinet'>FN</a>) after Coherent&rsquo;s downward Q4 preliminary results, which confirmed that the Chinese industrial laser market is still weak.</li><li>               The firm says II-VI and Fabrinet have notable exposure to the market, with Fabrinet serving as the contract manufacturer for Coherent&rsquo;s industrial lasers and II-VI getting about 10% of its revenue from China.&nbsp;</li><li>               B. Riley rates both companies at Neutral with II-VI at a $54 target and Fabrinet at $52.&nbsp;</li><li>               IIVI shares are&nbsp;<font color='red'>down 0.9%</font>&nbsp;to $38.62.&nbsp;</li><li>               FN shares are&nbsp;<font color='green'>up 0.1%</font>&nbsp;to $45.07. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3399284-coherent-dips-6_7-percent-lower-preliminary-q4-results\" target=\"_blank\">Coherent dips 6.7% on lower preliminary Q4 results</a> (Oct. 22)</li></ul><div class=\"tiny-share-widget\" data-id=\"3399311\" data-linked=\"B. Riley cautious on II-VI, Fabrinet after Coherent drop\" data-tweet=\"$IIVI $IIVI $FN - B. Riley cautious on II-VI, Fabrinet after Coherent drop https://seekingalpha.com/news/3399311-b-riley-cautious-on-ii-vi-fabrinet-after-coherent-drop?source=tweet\" data-url=\"https://seekingalpha.com/news/3399311-b-riley-cautious-on-ii-vi-fabrinet-after-coherent-drop\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:43 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399307\" data-ts=\"1540222626\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PHG\" target=\"_blank\">PHG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399307-koninklijke-philips-down-9-post-q3-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Koninklijke Philips down 9% post Q3 results</a></h4><ul>     <li>Koninklijke Philips NV (NYSE:<a href='https://seekingalpha.com/symbol/PHG' title='Koninklijke Philips NV'>PHG</a>)&nbsp;<font color='red'>drops 9%</font>&nbsp;on Q3 results that missed EPS and revenue estimates.</li>     <li>Comparable order intake increased 11% compared to Q317.</li>     <li>Adjusted EBITA margin improved by 40 bps to 13.2% of sales, including a 60 bps adverse currency impact, compared to 12.8% of sales in Q317.</li>     <li>Operating cash flow totaled &euro;265M, compared to&nbsp;&euro;295M year ago.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3399137-koninklijke-philips-nv-lower-earning-miss\" target=\"_blank\">Koninklijke Philips NV lower on earning miss</a> (Oct. 22)</li><li><a href=\"https://www.results.philips.com/#/downloads\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3399307\" data-linked=\"Koninklijke Philips down 9% post Q3 results\" data-tweet=\"$PHG - Koninklijke Philips down 9% post Q3 results https://seekingalpha.com/news/3399307-koninklijke-philips-down-9-post-q3-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3399307-koninklijke-philips-down-9-post-q3-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:37 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399306\" data-ts=\"1540222539\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVDA\" target=\"_blank\">NVDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399306-bofaml-semi-correction-normal-what-to-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BofAML: Semi correction normal, here&#39;s what to buy</a></h4><ul><li>        Bank of America Merrill Lynch says a 10% correction of the Philadelphia Semiconductor Index happens one to two times a year and the current one is the tenth since the recovery began in 2010.</li><li>               Analyst Vivek Arya says corrections average around 19%, suggesting the potential for another 5% downside to this current downturn.&nbsp;</li><li>               Good news: The recoveries tend to lead to 45%+ gains on average.&nbsp;</li><li>                  Arya sees an &ldquo;attractive risk-reward scenario once the volatility subsides&rdquo; and recommends high-quality, large-cap names like (<a href='https://seekingalpha.com/symbol/NVDA' title='NVIDIA Corporation'>NVDA</a> <font color='green'>+1.5%</font>), (<a href='https://seekingalpha.com/symbol/AVGO' title='Broadcom Limited'>AVGO</a> <font color='green'>+0.6%</font>), (<a href='https://seekingalpha.com/symbol/TXN' title='Texas Instruments Inc.'>TXN</a> <font color='green'>+1.3%</font>) and smid caps like (<a href='https://seekingalpha.com/symbol/MRVL' title='Marvell Technology Group, Ltd.'>MRVL</a> <font color='red'>-1.2%</font>), (<a href='https://seekingalpha.com/symbol/AMD' title='Advanced Micro Devices, Inc.'>AMD</a> <font color='green'>+6.8%</font>), (<a href='https://seekingalpha.com/symbol/NXPI' title='NXP Semiconductors'>NXPI</a> <font color='red'>-1.1%</font>), and (<a href='https://seekingalpha.com/symbol/ON' title='ON Semiconductor Corporation'>ON</a> <font color='red'>-0.1%</font>).    </li><li>               Texas Instruments reports earnings tomorrow after the market closes.&nbsp;</li><li>               Source: Bloomberg First Word.&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3399306\" data-linked=\"BofAML: Semi correction normal, here&#39;s what to buy\" data-tweet=\"$NVDA $NVDA $AVGO - BofAML: Semi correction normal, here&#39;s what to buy https://seekingalpha.com/news/3399306-bofaml-semi-correction-normal-what-to-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3399306-bofaml-semi-correction-normal-what-to-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:35 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>56&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399304\" data-ts=\"1540222138\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NCNA\" target=\"_blank\">NCNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399304-nucanas-acelarin-shows-positive-effect-in-first-line-biliary-tract-cancer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nucana&#39;s Acelarin shows positive effect in first-line biliary tract cancer</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/17306707-nucana-reports-additional-promising-clinical-data-nucminus-1031-acelarin-front-line-treatment\" target=\"_blank\">Results </a>from an open-label Phase 1b clinical trial evaluating NuCana's (<a href='https://seekingalpha.com/symbol/NCNA' title='NuCana plc'>NCNA</a> <font color='red'>-7.2%</font>) Alelarin, combined with the chemo agent cisplatin, in patients with advanced biliary tract cancer in a first-line setting showed a treatment effect. The data were presented at ESMO in Munich.</li><li>The response rate was 50% (n=7/14), including one complete responder, in the intent-to-treat population and 64% (n=7/11) in evaluable patients.</li><li>No new safety signals were observed.</li><li>A Phase 3 study is next up.</li><li>#ESMO</li></ul><div class=\"tiny-share-widget\" data-id=\"3399304\" data-linked=\"Nucana&#39;s Acelarin shows positive effect in first-line biliary tract cancer\" data-tweet=\"$NCNA - Nucana&#39;s Acelarin shows positive effect in first-line biliary tract cancer https://seekingalpha.com/news/3399304-nucanas-acelarin-shows-positive-effect-in-first-line-biliary-tract-cancer?source=tweet\" data-url=\"https://seekingalpha.com/news/3399304-nucanas-acelarin-shows-positive-effect-in-first-line-biliary-tract-cancer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:28 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399305\" data-ts=\"1540222086\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MU\" target=\"_blank\">MU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399305-raymond-james-resumes-micron-market-perform\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Raymond James resumes Micron at Market Perform</a></h4><ul><li>           Raymond James <a href=\"https://www.streetinsider.com/Downgrades/Raymond+James+Transfers+Coverage+on+Micron+Technology+%28MU%29%2C+Downgrades+to+Market+Perform/14726868.html\" target=\"_blank\">resumes</a> Micron (NASDAQ:<a href='https://seekingalpha.com/symbol/MU' title='Micron Technology Inc.'>MU</a>) with a Market Perform rating from a Strong Buy. </li><li> The company switched analysts with Chris Caso taking Micron from Michael Gibbs. </li><li> Micron shares are&nbsp;<font color='red'>down 1.8%&nbsp;</font>to $39.74.&nbsp;&nbsp; </li></ul><div class=\"tiny-share-widget\" data-id=\"3399305\" data-linked=\"Raymond James resumes Micron at Market Perform\" data-tweet=\"$MU - Raymond James resumes Micron at Market Perform https://seekingalpha.com/news/3399305-raymond-james-resumes-micron-market-perform?source=tweet\" data-url=\"https://seekingalpha.com/news/3399305-raymond-james-resumes-micron-market-perform\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>70&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399303\" data-ts=\"1540221998\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HAL\" target=\"_blank\">HAL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399303-halliburton-sinks-after-guiding-q4-eps-below-consensus-0_37-0_40\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Halliburton sinks after guiding Q4 EPS at below consensus $0.37-$0.40</a></h4><ul>     <li>Halliburton (<a href='https://seekingalpha.com/symbol/HAL' title='Halliburton Company'>HAL</a> <font color='red'>-2.3%</font>) falls as much as 3.5% after warning it <a href=\"https://www.reuters.com/article/us-halliburton-results/halliburton-forecasts-lower-fourth-quarter-profit-shares-fall-idUSKCN1MW1H8\" target=\"_blank\">expects Q4 EPS of $0.37-$0.40</a>, well below analyst consensus of $0.49, amid ongoing weakness in the North American hydraulic fracturing market.</li>     <li>HAL sees fracking work in Q4 to decline by a low double-digit percentage but it will not cut costs or infrastructure during the downturn, as it expects the U.S. onshore sector to find a bottom in the quarter as producers reset 2019 budgets, the company said in its earnings conference call.</li>     <li>HAL has seen demand for oilfield services weaken as U.S. producers trim spending and transportation bottlenecks in the Permian Basin pushed the price of regional crude lower.</li>     <li>The oilfield services ETF (<a href='https://seekingalpha.com/symbol/OIH' title='VanEck Vectors Oil Services ETF'>OIH</a> <font color='red'>-1.5%</font>) hits a 52-week low, and HAL peers are down: <a href='https://seekingalpha.com/symbol/SLB' title='Schlumberger Limited'>SLB</a> <font color='red'>-3.2%</font>, <a href='https://seekingalpha.com/symbol/WFT' title='Weatherford International Ltd.'>WFT</a> <font color='red'>-2.2%</font>, <a href='https://seekingalpha.com/symbol/BHGE' title='Baker Hughes, a GE company'>BHGE</a> <font color='red'>-1.7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3399303\" data-linked=\"Halliburton sinks after guiding Q4 EPS at below consensus $0.37-$0.40\" data-tweet=\"$HAL $HAL $OIH - Halliburton sinks after guiding Q4 EPS at below consensus $0.37-$0.40 https://seekingalpha.com/news/3399303-halliburton-sinks-after-guiding-q4-eps-below-consensus-0_37-0_40?source=tweet\" data-url=\"https://seekingalpha.com/news/3399303-halliburton-sinks-after-guiding-q4-eps-below-consensus-0_37-0_40\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399302\" data-ts=\"1540221610\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NCNA\" target=\"_blank\">NCNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399302-nucana-down-6-on-nucminus-3373-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NuCana down 6% on NUC-3373 data</a></h4><ul><li>Thinly traded NuCana (<a href='https://seekingalpha.com/symbol/NCNA' title='NuCana plc'>NCNA</a> <font color='red'>-6.4%</font>) is down on average volume following its <a href=\"https://seekingalpha.com/pr/17306925-nucana-presents-data-phase-study-nucminus-3373-esmo-2018\" target=\"_blank\">announcement </a>of additional data from a Phase 1 clinical trial evaluating NUC-3373 in patients with advanced solid tumors. The results were presented at ESMO in Munich.</li><li>In 36 metastatic patients, 8.3% (n=3/36) experienced stable cancer with responses lasting more than nine months at data cutoff.</li><li>NUC-3373 is an analog of the chemo agent 5-fluorouracil (5-FU) that the company say has the same efficacy with less side effects, including hand-foot syndrome (redness, swelling and pain in the palms of the hand or soles of the feet).</li><li>#ESMO</li></ul><div class=\"tiny-share-widget\" data-id=\"3399302\" data-linked=\"NuCana down 6% on NUC-3373 data\" data-tweet=\"$NCNA - NuCana down 6% on NUC-3373 data https://seekingalpha.com/news/3399302-nucana-down-6-on-nucminus-3373-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3399302-nucana-down-6-on-nucminus-3373-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:20 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399298\" data-ts=\"1540221188\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PETS\" target=\"_blank\">PETS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399298-petmed-express-leads-healthcare-winners-losers-stung-esmo-conference-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PetMed Express leads healthcare winners, losers stung by ESMO conference data</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/PETS' title='PetMed Express, Inc.'>PETS</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/CLGN' title='CollPlant'>CLGN</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/ARDM' title='Aradigm Corp.'>OTC:ARDM</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/DVAX' title='Dynavax Technologies Corporation'>DVAX</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/SRTS' title='Sensus Healthcare'>SRTS</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ADRO' title='Aduro Biotech'>ADRO</a> <font color='red'>-35%</font>. <a href='https://seekingalpha.com/symbol/ADAP' title='Adaptimmune Therapeutics plc'>ADAP</a> <font color='red'>-26%</font>. <a href='https://seekingalpha.com/symbol/MRTX' title='Mirati Therapeutics, Inc.'>MRTX</a> <font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/CLVS' title='Clovis Oncology'>CLVS</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/NTGN' title='Neon Therapeutics'>NTGN</a> <font color='red'>-16%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3399298\" data-linked=\"PetMed Express leads healthcare winners, losers stung by ESMO conference data\" data-tweet=\"$PETS $PETS $CLGN - PetMed Express leads healthcare winners, losers stung by ESMO conference data https://seekingalpha.com/news/3399298-petmed-express-leads-healthcare-winners-losers-stung-esmo-conference-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3399298-petmed-express-leads-healthcare-winners-losers-stung-esmo-conference-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399300\" data-ts=\"1540220844\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SVMK\" target=\"_blank\">SVMK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399300-two-initiations-for-svmk\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Two more initiations for SVMK</a></h4><ul><li>        Bank of America Merrill Lynch initiates SurveyMonkey parent (NASDAQ:<a href='https://seekingalpha.com/symbol/SVMK' title='SurveyMonkey'>SVMK</a>) at Buy with a $16 price target.</li><li>               Credit Suisse starts SVMK at Neutral with a $13 price target.&nbsp;</li><li>               Source: StreetAccount.&nbsp;</li><li>               SVMK shares are&nbsp;<font color='red'>down 8.5%</font>&nbsp;to $11.92. Shares are down&nbsp;<font color='red'>24.5%</font>&nbsp;since the IPO late last month and have felt pressure since last week&rsquo;s IPO filing from a competitor.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3399035-surveymonkey-drops-competitor-files-200m-ipo\" target=\"_blank\">SurveyMonkey drops as competitor files for $200M IPO</a> (Oct. 19)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3399140-jpmorgan-starts-svmk-overweight\" target=\"_blank\">JPMorgan starts SVMK at Overweight</a> (Oct. 22)</li></ul><div class=\"tiny-share-widget\" data-id=\"3399300\" data-linked=\"Two more initiations for SVMK\" data-tweet=\"$SVMK - Two more initiations for SVMK https://seekingalpha.com/news/3399300-two-initiations-for-svmk?source=tweet\" data-url=\"https://seekingalpha.com/news/3399300-two-initiations-for-svmk\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:07 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399296\" data-ts=\"1540220149\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/YGYI\" target=\"_blank\">YGYI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399296-select-beverage-stocks-track-lower\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Select beverage stocks track lower</a></h4><ul> <li>Youngevity International (NASDAQ:<a href='https://seekingalpha.com/symbol/YGYI' title='Youngevity International, Inc.'>YGYI</a>) is <font color='red'>down 16%</font> and New Age Beverages (NASDAQ:<a href='https://seekingalpha.com/symbol/NBEV' title='New Age Beverages Corporation'>NBEV</a>) is <font color='red'>13% lower</font> as investors back off the cannabis-beverage investing theme a bit more.</li> <li>Also with the beverage sector, DavidsTea (NASDAQ:<a href='https://seekingalpha.com/symbol/DTEA' title='DAVIDs TEA'>DTEA</a>) is <font color='red'>off 5.4%</font> and Reed's (NYSEMKT:<a href='https://seekingalpha.com/symbol/REED' title='Reed&#39;s, Inc.'>REED</a>) is <font color='red'>1.1% lower</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3399296\" data-linked=\"Select beverage stocks track lower\" data-tweet=\"$YGYI $YGYI $NBEV - Select beverage stocks track lower https://seekingalpha.com/news/3399296-select-beverage-stocks-track-lower?source=tweet\" data-url=\"https://seekingalpha.com/news/3399296-select-beverage-stocks-track-lower\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399293\" data-ts=\"1540219942\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LAIX\" target=\"_blank\">LAIX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399293-morgan-stanley-starts-laix-slight-downside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Morgan Stanley starts LAIX at slight downside</a></h4><ul><li>        Morgan Stanley initiates LAIX (NYSE:<a href='https://seekingalpha.com/symbol/LAIX' title='LAIX'>LAIX</a>) at Equal Weight with an $11.50 price target, a 3.4% downside to Friday&rsquo;s close.</li><li>               Source: StreetAccount.&nbsp;</li><li>               The Chinese AI-based learning company competes with the likes of privately held VIPKID, which raised $500M at an over $3B valuation earlier this year.&nbsp;</li><li>               LAIX shares are&nbsp;<font color='green'>up 0.9%</font>&nbsp;to $11.86 on a bit of a volatile day. Shares are&nbsp;<font color='red'>down 6%&nbsp;</font>since the IPO late last month.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3393467-laix-opens-first-day-16\" target=\"_blank\">LAIX opens its first day at $16</a> (Sept. 27)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3399088-chinese-stocks-jump-two-years\" target=\"_blank\">Chinese stocks jump most in two years</a> (Oct. 22)</li></ul><div class=\"tiny-share-widget\" data-id=\"3399293\" data-linked=\"Morgan Stanley starts LAIX at slight downside\" data-tweet=\"$LAIX - Morgan Stanley starts LAIX at slight downside https://seekingalpha.com/news/3399293-morgan-stanley-starts-laix-slight-downside?source=tweet\" data-url=\"https://seekingalpha.com/news/3399293-morgan-stanley-starts-laix-slight-downside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:52 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399290\" data-ts=\"1540219253\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FRAN\" target=\"_blank\">FRAN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399290-francescasplus-8-after-hitting-multi-year-low\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Francesca&#39;s +8% after hitting multi-year low</a></h4><ul> <li>Francesca's (NASDAQ:<a href='https://seekingalpha.com/symbol/FRAN' title='Francesca&#39;s Holdings Corp.'>FRAN</a>) is <font color='green'>up 7.7%</font> as shares bounce hard off the multi-year low struck on Friday when the retailer traded as low as $2.79.</li>  <li>Short interest on Francesca's is at almost 25% of total float.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3399290\" data-linked=\"Francesca&#39;s +8% after hitting multi-year low\" data-tweet=\"$FRAN - Francesca&#39;s +8% after hitting multi-year low https://seekingalpha.com/news/3399290-francescasplus-8-after-hitting-multi-year-low?source=tweet\" data-url=\"https://seekingalpha.com/news/3399290-francescasplus-8-after-hitting-multi-year-low\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399284\" data-ts=\"1540218689\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/COHR\" target=\"_blank\">COHR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399284-coherent-dips-6_7-on-lower-preliminary-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Coherent dips 6.7% on lower preliminary Q4 results</a></h4><ul><li>        Coherent (NASDAQ:<a href='https://seekingalpha.com/symbol/COHR' title='Coherent, Inc.'>COHR</a>) <a href=\"https://seekingalpha.com/pr/17307418-coherent-inc-announces-preliminary-fourth-fiscal-quarter-2018-financial-results\" target=\"_blank\">announces</a> preliminary Q4 results with revenue of $460M to $461M (was: $465M to $485M), non-GAAP gross margin of 43% to 44% (was: 46% to 49%), and operating margin of 22% to 23% (was: 25% to 28%).</li><li>               The company blames end of quarter execution challenges in a German manufacturing site and the softening demand environment in China.&nbsp;</li><li>                  The earnings call is scheduled for November 6. &nbsp;   </li><li>               COHR shares are&nbsp;<font color='red'>down 6.7%</font>&nbsp;to $123.57.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3399284\" data-linked=\"Coherent dips 6.7% on lower preliminary Q4 results\" data-tweet=\"$COHR - Coherent dips 6.7% on lower preliminary Q4 results https://seekingalpha.com/news/3399284-coherent-dips-6_7-on-lower-preliminary-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3399284-coherent-dips-6_7-on-lower-preliminary-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399283\" data-ts=\"1540218615\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CEA\" target=\"_blank\">CEA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399283-asian-airline-stocks-break-higher\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Asian airline stocks break higher</a></h4><ul> <li>Asian airline carriers are riding the broad market rally in China higher.</li> <li>Notable gainers include China Eastern Airline (<a href='https://seekingalpha.com/symbol/CEA' title='China Eastern Airlines Corporation Limited'>CEA</a> <font color='green'>+6.6%</font>), Singapore Airlines (<a href='https://seekingalpha.com/symbol/SINGF' title='Singapore Airlines Ltd.'>OTCPK:SINGF</a>), Cathay Pacific Airways (<a href='https://seekingalpha.com/symbol/CPCAF' title='Cathay Pacific Airways, Ltd.'>OTCPK:CPCAF</a>) and China Southern Airlines (<a href='https://seekingalpha.com/symbol/ZNH' title='China Southern Airlines Company Limited'>ZNH</a> <font color='green'>+5.4%</font>).</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3399283\" data-linked=\"Asian airline stocks break higher\" data-tweet=\"$CEA $CEA $SINGF - Asian airline stocks break higher https://seekingalpha.com/news/3399283-asian-airline-stocks-break-higher?source=tweet\" data-url=\"https://seekingalpha.com/news/3399283-asian-airline-stocks-break-higher\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:30 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399282\" data-ts=\"1540218576\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTR\" target=\"_blank\">NTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399282-nutrien-says-sqm-top-shareholder-blocking-tianqi-deal-for-personal-benefit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nutrien says SQM top shareholder blocking Tianqi deal for personal benefit</a></h4><ul>     <li>Nutrien (<a href='https://seekingalpha.com/symbol/NTR' title='Nutrien Ltd.'>NTR</a> <font color='red'>-2%</font>), whose attempt to sell its 24% stake in&nbsp;Chilean&nbsp;lithium miner&nbsp;SQM (<a href='https://seekingalpha.com/symbol/SQM' title='Chemical & Mining Co. of Chile Inc.'>SQM</a> <font color='red'>-0.4%</font>) to China's Tianqi  Lithium has been stalled in a dispute about competitive risks, accuses SQM&rsquo;s largest shareholder of <a href=\"http://www.mining.com/nutrien-accuses-sqm-top-shareholder-seeking-block-deal-tianqi-personal-benefit/\" target=\"_blank\">blocking the deal for personal benefit</a>.</li>     <li>NTR executive VP Michael Webb told Chilean newspaper <em>El Mercurio</em> over the weekend that Julio Ponce, SQM&rsquo;s top shareholder and former chairman, was trying to block the $4.1B deal only to keep his dominant position in the company.</li>     <li>&ldquo;His stance is undoubtedly hypocritical, considering that we know he was trying for a year to sell 80% of his investment in SQM to a number of actors, including Tianqi,&rdquo; Webb said, adding that NTR would &ldquo;protect  its interests.&rdquo;</li><li>The sale of NTR&rsquo;s stake in SQM was <a href=\"https://seekingalpha.com/news/3395331-chinas-tianqi-can-buy-25-percent-stake-sqm-chilean-antitrust-court-rules\" target=\"_blank\">approved</a> by Chile&rsquo;s antitrust regulator, but Ponce, through his investment firm Pampa Group, said the deal would give Tianqi, a top competitor,  &ldquo;unrestricted access&rdquo; to &ldquo;confidential and sensitive information.&rdquo;</li> </ul><div class=\"tiny-share-widget\" data-id=\"3399282\" data-linked=\"Nutrien says SQM top shareholder blocking Tianqi deal for personal benefit\" data-tweet=\"$NTR $NTR $SQM - Nutrien says SQM top shareholder blocking Tianqi deal for personal benefit https://seekingalpha.com/news/3399282-nutrien-says-sqm-top-shareholder-blocking-tianqi-deal-for-personal-benefit?source=tweet\" data-url=\"https://seekingalpha.com/news/3399282-nutrien-says-sqm-top-shareholder-blocking-tianqi-deal-for-personal-benefit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399281\" data-ts=\"1540218385\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OPB\" target=\"_blank\">OPB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399281-opus-bank-sinks-15-after-q3-eps-misses-nim-contracts\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Opus Bank sinks 15% after Q3 EPS misses, NIM contracts</a></h4><ul><li>Opus Bank (NASDAQ:<a href='https://seekingalpha.com/symbol/OPB' title='Opus Bank'>OPB</a>) sinks after <a href=\"https://seekingalpha.com/pr/17306936-opus-bank-announces-third-quarter-2018-results\" target=\"_blank\">Q3 EPS</a> misses consensus by 31% and net interest margin contracts on higher deposit costs.</li><li>\"We continue to battle through the industry-wide headwinds of elevated loan prepayments and rising cost of deposits, which negatively impacted our net interest margin,\" says President and CEO Stephen H. Gordon.</li><li>In addition, losses on two Enterprise Value loan relationships weren't equally offset by reserve releases as they were in prior quarters.</li><li>Enterprise Value loans decreased 80% since Q4 2016 to $184.5M as of Sept. 30, 2018, of which 66% is pass-rated. Enterprise Value loans have been further reduced to $168.5M as of Oct. 19, 2018.</li><li>Q3 EPS of 25 cents declines from 40 cents in Q2 and 54 cents in Q3 2017.</li><li>Q3 net interest margin fell 9 basis points&nbsp; Q/Q to 2.98% on a 14 bps increase in cost of deposits to 0.71% partly offset by higher average yield on loans and investment securities.</li><li>Q3 new loan fundings rose 47% to $435.7M from $295.6M in Q2 and up 16% from $375.4M in Q3 2017.</li><li>Q3 loan loss provision of $8.2M vs. negative provision of $213,000 in Q2 and negative provision of $10.6M in Q3 2017; net charge-offs of $8.4M, unchanged from Q2 and vs. $1.1M net recoveries in Q3 207.</li><li>Common equity Tier 1 ratio of 11.75% as of Sept. 30, 2018 vs. 11.85% at June 30, 2018 and 11.14% at Sept. 30, 2017.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3399138-opus-misses-0_11-misses-revenue\" target=\"_blank\">Opus misses by $0.11, misses on revenue</a> (Oct. 22)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3399139-opus-declares-0_11-dividend\" target=\"_blank\">Opus declares $0.11 dividend</a> (Oct. 22)</li></ul><div class=\"tiny-share-widget\" data-id=\"3399281\" data-linked=\"Opus Bank sinks 15% after Q3 EPS misses, NIM contracts\" data-tweet=\"$OPB - Opus Bank sinks 15% after Q3 EPS misses, NIM contracts https://seekingalpha.com/news/3399281-opus-bank-sinks-15-after-q3-eps-misses-nim-contracts?source=tweet\" data-url=\"https://seekingalpha.com/news/3399281-opus-bank-sinks-15-after-q3-eps-misses-nim-contracts\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399280\" data-ts=\"1540218098\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRAY\" target=\"_blank\">CRAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399280-cray-announces-ai-strategic-partnership\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cray announces AI strategic partnership</a></h4><ul><li>        Cray (NASDAQ:<a href='https://seekingalpha.com/symbol/CRAY' title='Cray Inc'>CRAY</a>) and Canadian AI solutions provider Stradigi AI <a href=\"https://seekingalpha.com/pr/17307379-cray-stradigi-ai-partner-crack-code-enterprise-ai-implementation\" target=\"_blank\">announce</a> a strategic partnership combining Stradigi&rsquo;s specialized data science skills with Cray&rsquo;s supercomputing expertise and advanced technology.</li><li>               Under the partnership, Cray will package its Accel AI starter kit with Stradigi&rsquo;s domain expertise for tailored solutions for proofs-of-concept to deployment at scale.&nbsp;</li><li>               Cray shares are&nbsp;<font color='green'>up 0.7%</font>&nbsp;to $20.11.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3399280\" data-linked=\"Cray announces AI strategic partnership\" data-tweet=\"$CRAY - Cray announces AI strategic partnership https://seekingalpha.com/news/3399280-cray-announces-ai-strategic-partnership?source=tweet\" data-url=\"https://seekingalpha.com/news/3399280-cray-announces-ai-strategic-partnership\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:21 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399278\" data-ts=\"1540217902\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RYAAY\" target=\"_blank\">RYAAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399278-ryanair-holdingsplus-2_5-post-h1-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ryanair Holdings +2.5% post H1 results</a></h4><ul><li>Ryanair Holdings (<a href='https://seekingalpha.com/symbol/RYAAY' title='Ryanair Holdings PLC'>RYAAY</a> <font color='green'>+2.5%</font>) <u><a href=\"https://investor.ryanair.com/results/h1-results-fy19/\" target=\"_blank\">reports H1</a></u>&nbsp;revenue growth of 9.3% Y/Y to &euro;4.84B.</li><li>Ancillary revenue rose 27% Y/Y to &euro;1.3B &amp; Laudamotion holding increased to 75%</li><li>Traffic grew 6% to 76.6M &amp; for FY19 expect s traffic will grow to 141M</li><li>Average fare fell 3% to under &euro;46, as Guests were 72.1M (+6% Y/Y).</li><li>The company took delivery of 23 new B737s and launched over 100 new S.18 routes.</li><li>Agreements were aslo signed with Irish, UK, Italian, Portuguese (pilots) &amp; German (cabin crew) unions.</li><li>&euro;540m returned to shareholders via buybacks.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3399208-ryanair-holdings-reports-1h-results\" target=\"_blank\">Ryanair Holdings reports 1H results</a> (Oct. 22)</li></ul><div class=\"tiny-share-widget\" data-id=\"3399278\" data-linked=\"Ryanair Holdings +2.5% post H1 results\" data-tweet=\"$RYAAY - Ryanair Holdings +2.5% post H1 results https://seekingalpha.com/news/3399278-ryanair-holdingsplus-2_5-post-h1-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3399278-ryanair-holdingsplus-2_5-post-h1-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:18 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399276\" data-ts=\"1540217494\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTMX\" target=\"_blank\">CTMX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399276-cytomx-down-10-on-cxminus-072-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CytomX down 10% on CX-072 data</a></h4><ul><li>CytomX Therapeutics (<a href='https://seekingalpha.com/symbol/CTMX' title='CytomX Therapeutics'>CTMX</a> <font color='red'>-9.7%</font>) slips on below-average volume in early trade following its <a href=\"https://seekingalpha.com/pr/17306886-cytomx-therapeutics-presents-clinical-data-probody-platform-cxminus-072-2018-esmo-annual\" target=\"_blank\">announcement </a>of results from a Phase 1/2 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03013491?lead=cytomx+Therapeutics&amp;rank=4\" target=\"_blank\">PROCLAIM-072</a>, evaluating lead candidate CX-072, alone or in combination with Bristol-Myers Squibb's Yervoy (ipilimumab) or Roche's Zelboraf (vemurafenib), in patients with advanced unresectable solid tumors. The data were presented at ESMO in Munich.</li><li>The objective response rate &#40;ORR&#41; in 38 evaluable patients in the monotherapy arm was 8% (n=3/38). The disease control rate &#40;DCR&#41; (responders + stable cancer) was 47% (n=18/38).</li><li>Dosing in the expansion arm (at a higher dose of 10 mg/kg) is underway.</li><li>In 14 evaluable patients who received CX-072 + Yervoy, the ORR was 21% (n=3/14) with a DCR of 43% (n=6/14).</li><li>#ESMO</li></ul><div class=\"tiny-share-widget\" data-id=\"3399276\" data-linked=\"CytomX down 10% on CX-072 data\" data-tweet=\"$CTMX - CytomX down 10% on CX-072 data https://seekingalpha.com/news/3399276-cytomx-down-10-on-cxminus-072-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3399276-cytomx-down-10-on-cxminus-072-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:11 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399275\" data-ts=\"1540217255\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FIVN\" target=\"_blank\">FIVN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399275-five9-appoints-salesforce-vet-cmo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Five9 appoints Salesforce vet as CMO</a></h4><ul><li>        Five9 (NASDAQ:<a href='https://seekingalpha.com/symbol/FIVN' title='Five9, Inc.'>FIVN</a>) <a href=\"https://seekingalpha.com/pr/17307317-ryan-kam-recognized-marketing-leader-salesforce-appdynamics-joins-five9-cmo\" target=\"_blank\">appoints</a> Ryan Kam as Chief Marketing Officer.</li><li>                  Kam joins from AppDynamics, where he rebranded the company and directed its IPO roadshow.    </li><li>               Kam previously served in a range of roles at Salesforce including creative director for the Dreamforce conference.&nbsp;</li><li>               Five9 shares are&nbsp;<font color='green'>up 0.9%</font>&nbsp;to $37.46.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3399275\" data-linked=\"Five9 appoints Salesforce vet as CMO\" data-tweet=\"$FIVN - Five9 appoints Salesforce vet as CMO https://seekingalpha.com/news/3399275-five9-appoints-salesforce-vet-cmo?source=tweet\" data-url=\"https://seekingalpha.com/news/3399275-five9-appoints-salesforce-vet-cmo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:07 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399267\" data-ts=\"1540216640\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SALT\" target=\"_blank\">SALT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399267-scorpio-bulkers-cruises-positive-territory\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Scorpio Bulkers cruises into positive territory</a></h4><ul> <li>Deuces are wild at Scorpio Bulkers (NYSE:<a href='https://seekingalpha.com/symbol/SALT' title='Scorpio Bulkers Inc'>SALT</a>) as shares track <font color='green'>2.22% higher</font> after an initial post-earnings dip.</li> <li>Scorpio delivered in-line EBITDA of $29M during the quarter and reported a slightly lower outstanding balance at its credit facility than a year ago ($803M vs. $815M).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3399263-scorpio-bulkers-lower-q3-earnings\" target=\"_blank\">Scorpio Bulkers lower after Q3 earnings</a> (Oct. 22)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3399267\" data-linked=\"Scorpio Bulkers cruises into positive territory\" data-tweet=\"$SALT - Scorpio Bulkers cruises into positive territory https://seekingalpha.com/news/3399267-scorpio-bulkers-cruises-positive-territory?source=tweet\" data-url=\"https://seekingalpha.com/news/3399267-scorpio-bulkers-cruises-positive-territory\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:57 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399264\" data-ts=\"1540215853\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NFLX\" target=\"_blank\">NFLX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399264-investors-size-up-netflix-after-2b-debt-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Investors size up Netflix after $2B debt deal</a></h4><ul> <li>Netflix (NASDAQ:<a href='https://seekingalpha.com/symbol/NFLX' title='Netflix, Inc.'>NFLX</a>) is <font color='red'>down 1.49%</font> after announcing that it plans to raise $2B more in debt to fund content acquisitions and potentially make M&amp;A moves.</li> <li>Interestingly, the debt is being split between U.S. dollar-denominated notes and Euro-denominated notes.</li> <li>The company has an investor call scheduled for noon to discuss more details.</li><li>Pricing on the new notes is expected to be announced tomorrow.</li> <li>Ratings watch:&nbsp;Moody's long-term credit rating on Netflix already sits in \"speculative\" territory at Ba3.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3399234-netflix-proposes-2b-offering-senior-notes\" target=\"_blank\">Netflix proposes $2B offering of senior notes</a> (Oct. 22)</li></ul><div class=\"tiny-share-widget\" data-id=\"3399264\" data-linked=\"Investors size up Netflix after $2B debt deal\" data-tweet=\"$NFLX - Investors size up Netflix after $2B debt deal https://seekingalpha.com/news/3399264-investors-size-up-netflix-after-2b-debt-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3399264-investors-size-up-netflix-after-2b-debt-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>52&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399257\" data-ts=\"1540215713\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVEO\" target=\"_blank\">AVEO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399257-aveo-down-4-on-mid-stage-tivozanib-data-in-kidney-cancer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AVEO down 4% on mid-stage tivozanib data in kidney cancer</a></h4><ul><li>AVEO Oncology (<a href='https://seekingalpha.com/symbol/AVEO' title='AVEO Pharmaceuticals, Inc.'>AVEO</a> <font color='red'>-4.4%</font>) is down out of the gate this morning following the <a href=\"https://www.aveooncology.com/wp-content/uploads/2018/10/AVEO-TiNivo-ESMO.pdf\" target=\"_blank\">presentation </a>of Phase 1b/2 data at ESMO on FOTIVDA (tivozanib), combined with Bristol-Myers Squibb's (<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a> <font color='red'>-5.6%</font>) OPDIVO (nivolumab), in patients with advanced/metastatic renal cell carcinoma &#40;RCC&#41;.</li><li>The objective response rate &#40;ORR&#41; was 56% (n=14/25) in patients who had received at least one prior line of therapy, including one complete responder. The disease control rate (responders + stable cancer) was 96% (n=24/25). Most patients showed cancer control for at least 48 weeks. 72% (n=18/25) experienced tumor shrinkage at least 25%.</li><li>In the <a href=\"http://www.ascopost.com/issues/june-10-2018/checkmate-214/\" target=\"_blank\">CheckMate-214</a> study, the overall survival at year 1 for Opdivo + Yervoy was 80% and 75% at 1.5 years. The ORR was 42% including a 9% complete response rate.</li><li><a href=\"http://www.aveooncology.com/our-product-candidates/tivozanib/\" target=\"_blank\">Tivozanib&nbsp;</a>is an oral, once-daily, vascular endothelial growth factor &#40;VEGF&#41; tyrosine kinase inhibitor &#40;TKI&#41;. It is designed to optimize VEGF blockade while minimizing toxic side effects.</li><li>#ESMO</li></ul><div class=\"tiny-share-widget\" data-id=\"3399257\" data-linked=\"AVEO down 4% on mid-stage tivozanib data in kidney cancer\" data-tweet=\"$AVEO $AVEO $BMY - AVEO down 4% on mid-stage tivozanib data in kidney cancer https://seekingalpha.com/news/3399257-aveo-down-4-on-mid-stage-tivozanib-data-in-kidney-cancer?source=tweet\" data-url=\"https://seekingalpha.com/news/3399257-aveo-down-4-on-mid-stage-tivozanib-data-in-kidney-cancer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399262\" data-ts=\"1540215477\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TCF\" target=\"_blank\">TCF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399262-on-tcf-financial-q3-nim-ticks-down-q-q-roace-improves\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on TCF Financial Q3: NIM ticks down Q/Q, ROACE improves</a></h4><ul><li>TCF Financial (NYSE:<a href='https://seekingalpha.com/symbol/TCF' title='TCF Financial Corporation'>TCF</a>) <a href=\"https://seekingalpha.com/pr/17307139-tcf-reports-quarterly-net-income-86_2-million-diluted-earnings-per-common-share-51-cents\" target=\"_blank\">Q3 EPS of 51 cents</a> exceeds consensus by 3 cents; Q3 EPS increases from adjusted EPS of 49 cents in Q2 and 29 cents in Q3 2017.</li><li>TCF&nbsp;<font color='red'>-0.6%</font>&nbsp;in early trading.</li><li>Q3 net interest income $249.1M vs. $250.8M in Q2 and $234.1M in Q3 2017; net interest margin of 4.66% slips 1 basis point from Q2 and is up 5 bps from a year ago.</li><li>Q3 noninterest income of $116.4M rose 2.1% from Q2 and 6.6% Y/Y; increases from both periods were primarily due to increased leasing and equipment finance non-interest income, partially offset by decreased servicing fee income due to the continued run-off in the auto finance serviced for others portfolio.</li><li>Auto finance portfolio run-off of $328.1M in Q3 and $924.5M YTD.</li><li>Adjusted return on average common equity of 14.44% vs. 14.11% in Q2 and 8.44% a year ago.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3399177-tcf-financial-beats-0_03-misses-revenue\" target=\"_blank\">TCF Financial beats by $0.03, misses on revenue</a> (Oct. 22)</li></ul><div class=\"tiny-share-widget\" data-id=\"3399262\" data-linked=\"More on TCF Financial Q3: NIM ticks down Q/Q, ROACE improves\" data-tweet=\"$TCF - More on TCF Financial Q3: NIM ticks down Q/Q, ROACE improves https://seekingalpha.com/news/3399262-on-tcf-financial-q3-nim-ticks-down-q-q-roace-improves?source=tweet\" data-url=\"https://seekingalpha.com/news/3399262-on-tcf-financial-q3-nim-ticks-down-q-q-roace-improves\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:37 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399261\" data-ts=\"1540215458\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SEED\" target=\"_blank\">SEED</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399261-origin-agritechplus-20-new-strategic-investor-buys-1_4m-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Origin Agritech +20% as new strategic investor buys 1.4M shares</a></h4><ul>     <li>Origin Agritech (<a href='https://seekingalpha.com/symbol/SEED' title='Origin Agritech Limited'>SEED</a> <font color='green'>+22.4%</font>) pops at the open following news that new strategic investor Longhan Investment Management <a href=\"https://seekingalpha.com/pr/17306942-origin-agritech-announces-new-strategic-investor\" target=\"_blank\">agrees to purchase</a> nearly 1.4M common shares for an aggregate purchase price of nearly $7.5M.</li>     <li><a href=\"https://seekingalpha.com/pr/17303683-origin-announces-strategic-cooperation-agreement-longhan-investment-management-integrated\" target=\"_blank\">Last week</a>, Origin and Longhan said they would work together to start the commercialization of  Integrated Saline-Alkaline Land Reclamation technology in 2019, both in China and globally.</li>     <li>Origin  and Longhan say they plan to integrate seed treatment, soil treatment technologies, and seed breeding and biotechnology, as well as Origin's agricultural business platform.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3399261\" data-linked=\"Origin Agritech +20% as new strategic investor buys 1.4M shares\" data-tweet=\"$SEED - Origin Agritech +20% as new strategic investor buys 1.4M shares https://seekingalpha.com/news/3399261-origin-agritechplus-20-new-strategic-investor-buys-1_4m-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3399261-origin-agritechplus-20-new-strategic-investor-buys-1_4m-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399254\" data-ts=\"1540214985\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAOI\" target=\"_blank\">AAOI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399254-needham-aaoi-sell-off-is-overdone-aaoiplus-2_7\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Needham: AAOI sell-off is &quot;overdone&quot;; AAOI +2.7%</a></h4><ul><li>        Needham analyst Alex Henderson says the Applied Optoelectronics (NASDAQ:<a href='https://seekingalpha.com/symbol/AAOI' title='Applied Optoelectronics, Inc.'>AAOI</a>) &ldquo;sell-off is overdone.&rdquo;</li><li>               Henderson says the &ldquo;outlook could be much better than people think&rdquo; and expects demand for 100G transceivers to double with stable pricing continuing into CY19.&nbsp;</li><li>               The analyst notes that the previous customer halt is no longer an issue.&nbsp;</li><li>               Rating reiterated at Buy with a $35 price target.&nbsp;</li><li>               Source: Bloomberg First Word. &nbsp;&nbsp;</li><li>                  AAOI shares are&nbsp;<font color='green'>up 2.7%&nbsp;</font>premarket to $22.49. Shares have&nbsp;<font color='red'>dropped 33%</font>&nbsp;in the past month,&nbsp;<font color='red'>47.8%</font>&nbsp;in the quarter, and&nbsp;<font color='red'>42%</font>&nbsp;YTD.    &nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3399254\" data-linked=\"Needham: AAOI sell-off is &quot;overdone&quot;; AAOI +2.7%\" data-tweet=\"$AAOI - Needham: AAOI sell-off is &quot;overdone&quot;; AAOI +2.7% https://seekingalpha.com/news/3399254-needham-aaoi-sell-off-is-overdone-aaoiplus-2_7?source=tweet\" data-url=\"https://seekingalpha.com/news/3399254-needham-aaoi-sell-off-is-overdone-aaoiplus-2_7\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399253\" data-ts=\"1540214979\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JTPY\" target=\"_blank\">JTPY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399253-china-tech-names-lead-premarket-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">China tech names lead premarket gainers</a></h4><ul><li><a href='https://seekingalpha.com/symbol/JTPY' title='JetPay Corporation'>JTPY</a> <font color='green'>+143%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3399213-ncr-acquire-jetpay-184m\" target=\"_blank\">acquisition</a> by NCR.</li><li><a href='https://seekingalpha.com/symbol/NETE' title='Net Element International, Inc.'>NETE</a> <font color='green'>+65%</font>&nbsp;on the <a href=\"https://seekingalpha.com/pr/17307229-net-elements-unified-payments-launches-compliant-payments-solution-legal-cannabis-industry\" target=\"_blank\">launch</a> of a secure and compliant payment processing offering aimed at the legal cannabis industry.</li><li><a href='https://seekingalpha.com/symbol/CLGN' title='CollPlant'>CLGN</a> <font color='green'>+61%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3399111-collplant-united-therapeutics-ink-deal-3d-bioprinting-solid-organ-scaffolds-human-transplants\" target=\"_blank\">deal</a> for 3D bioprinting of solid-organ scaffolds for human transplants.</li><li><a href='https://seekingalpha.com/symbol/ARII' title='American Railcar Industries, Inc.'>ARII</a> <font color='green'>+51%</font>&nbsp;on merger <a href=\"https://seekingalpha.com/news/3399136-american-railcar-industries-announces-merger-agreement\" target=\"_blank\">agreement</a>.</li><li><a href='https://seekingalpha.com/symbol/TOPS' title='TOP Ships Inc.'>TOPS</a> <font color='green'>+38%</font>.</li><li><a href='https://seekingalpha.com/symbol/SLS' title='SELLAS Life Sciences Group, Inc.'>SLS</a> <font color='green'>+28%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/17306966-sellas-life-sciences-announces-positive-final-data-triple-negative-breast-cancer-patients\" target=\"_blank\">positive</a> final data in triple negative breast cancer patients from phase 2b clinical trial.</li><li><a href='https://seekingalpha.com/symbol/DCIX' title='Diana Containerships Inc.'>DCIX</a> <font color='green'>+25%</font>.</li><li><a href='https://seekingalpha.com/symbol/DVAX' title='Dynavax Technologies Corporation'>DVAX</a> <font color='green'>+19%</font>&nbsp;on SD-101 + Keytruda <a href=\"https://seekingalpha.com/news/3399146-dynavax-18-percent-premarket-sdminus-101-keytruda-data-melanoma\" target=\"_blank\">data</a> in melanoma.</li><li><a href='https://seekingalpha.com/symbol/SEED' title='Origin Agritech Limited'>SEED</a> <font color='green'>+18%</font>&nbsp;on share subscription <a href=\"https://seekingalpha.com/pr/17306942-origin-agritech-announces-new-strategic-investor\" target=\"_blank\">agreement</a> with Longhan Investment Management.</li><li><a href='https://seekingalpha.com/symbol/SINO' title='Sino-Global Shipping America, Ltd.'>SINO</a> <font color='green'>+18%</font>.</li><li><a href='https://seekingalpha.com/symbol/AYTU' title='Aytu BioScience, Inc.'>AYTU</a> <font color='green'>+17%</font>.</li><li><a href='https://seekingalpha.com/symbol/ESEA' title='Euroseas Ltd.'>ESEA</a> <font color='green'>+16%</font>.</li><li><a href='https://seekingalpha.com/symbol/GLBS' title='Globus Maritime Ltd.'>GLBS</a> <font color='green'>+16%</font>.</li><li><a href='https://seekingalpha.com/symbol/MYSZ' title='MySize Inc.'>MYSZ</a> <font color='green'>+13%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/17307200-size-partners-lightspeed-provide-mysizeid-mobile-measurement-solution-e-retailers-worldwide\" target=\"_blank\">partnering</a> with&nbsp;lightspeed, to provide access to its MySizeID&trade; mobile measurement solution to e-retailers worldwide.</li><li><a href='https://seekingalpha.com/symbol/VTVT' title='vTv Therapeutics'>VTVT</a> <font color='green'>+10%</font>.</li><li><a href='https://seekingalpha.com/symbol/HCHC' title='HC2 Holdings, Inc.'>HCHC</a> <font color='green'>+9%</font>&nbsp;on possible <a href=\"https://seekingalpha.com/news/3399223-hc2-5-percent-possible-sale-global-marine\" target=\"_blank\">sale</a> of Global Marine.</li><li><a href='https://seekingalpha.com/symbol/IGC' title='India Globalization Capital, Inc'>OTC:IGC</a> <font color='green'>+9%</font>.</li><li><a href='https://seekingalpha.com/symbol/CRMD' title='CorMedix Inc.'>CRMD</a> <font color='green'>+7%</font>.</li><li><a href='https://seekingalpha.com/symbol/YNDX' title='Yandex N.V.'>YNDX</a> <font color='green'>+7%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3399168-yandex-says-regularly-receives-offers-sberbank-denial\" target=\"_blank\">receiving offers</a> after Sberbank denial.</li><li><a href='https://seekingalpha.com/symbol/MOMO' title='Momo'>MOMO</a> <font color='green'>+7%</font>.</li><li><a href='https://seekingalpha.com/symbol/NVIV' title='InVivo Therapeutics Holdings Corp'>NVIV</a> <font color='green'>+7%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3394383-invivo-therapeutics-8-percent-collaborating-privately-held-q-therapeutics\" target=\"_blank\">collaborating</a> with privately held Q Therapeutics.</li><li><a href='https://seekingalpha.com/symbol/PDD' title='Pinduoduo'>PDD</a> <font color='green'>+7%</font>.</li><li><a href='https://seekingalpha.com/symbol/SOGO' title='Sogou'>SOGO</a> <font color='green'>+7%.&nbsp;</font></li><li><a href='https://seekingalpha.com/symbol/TROV' title='TrovaGene, Inc.'>TROV</a>&nbsp;<font color='green'>+6%.&nbsp;</font></li><li><a href='https://seekingalpha.com/symbol/NIO' title='NIO'>NIO</a>&nbsp;<font color='green'>+6%&nbsp;</font>after Credit Suisse initiation.</li></ul><div class=\"tiny-share-widget\" data-id=\"3399253\" data-linked=\"China tech names lead premarket gainers\" data-tweet=\"$JTPY $JTPY $NETE - China tech names lead premarket gainers https://seekingalpha.com/news/3399253-china-tech-names-lead-premarket-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3399253-china-tech-names-lead-premarket-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}